NBER WORKING PAPER SERIES

WHICH MODELS CAN WE TRUST TO EVALUATE CONSUMER DECISION MAKING?
COMMENT ON â€œCHOICE INCONSISTENCIES AMONG THE ELDERLYâ€
Jonathan D. Ketcham
Nicolai V. Kuminoff
Christopher A. Powers
Working Paper 21387
http://www.nber.org/papers/w21387

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
July 2015

We are grateful to Jeremy Fox, Ben Handel, Claudio Lucarelli, Eugenio Miravete, John Romley, Dan
Silverman, and Kerry Smith for insights on this research, and to Jason Abaluck, Jonathan Gruber,
two anonymous referees, and the editor Pinelope Goldberg for helpful comments and suggestions
on prior drafts. The views expressed herein are those of the authors and do not necessarily reflect the
views of the National Bureau of Economic Research.
NBER working papers are circulated for discussion and comment purposes. They have not been peerreviewed or been subject to the review by the NBER Board of Directors that accompanies official
NBER publications.
Â© 2015 by Jonathan D. Ketcham, Nicolai V. Kuminoff, and Christopher A. Powers. All rights reserved.
Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided
that full credit, including Â© notice, is given to the source.

Which Models Can We Trust to Evaluate Consumer Decision Making? Comment on â€œChoice
Inconsistencies among the Elderlyâ€
Jonathan D. Ketcham, Nicolai V. Kuminoff, and Christopher A. Powers
NBER Working Paper No. 21387
July 2015
JEL No. D12,I11,I38
ABSTRACT
Neoclassical and psychological models of consumer behavior often make divergent predictions for
the welfare effects of paternalistic policies, leaving wide scope for researchersâ€™ choice of a model
to influence their policy conclusions. We develop a framework to reduce this model uncertainty and
apply it to administrative data on consumer decision making in Medicare Part D. Consumersâ€™ choices
for prescription drug insurance plans can be explained by Abaluck and Gruberâ€™s (AER 2011) model
of utility maximization with psychological biases or by a neoclassical version of their model that
precludessuch biases. We evaluate these competing hypotheses using nonparametric tests of utility
maximizationand a trio of model validation tests. We find that 79% of enrollment decisions in
Medicare Part D from2006-2010 satisfied basic axioms of consumer preference theory under the
assumptions of full information,zero transaction cost, and no measurement error. The validation
tests provide evidence against widespreadpsychological biases. In particular, we find that precluding
psychological biases improves the structuralmodelâ€™s out-of-sample predictions for consumer behavior.

Jonathan D. Ketcham
Associate Professor
Department of Marketing, Box 4106
W.P. Carey School of Business
Arizona State University
300 E. Lemon Street
Tempe, AZ 85287-4106
ketcham@asu.edu
Nicolai V. Kuminoff
Department of Economics
Arizona State University
P.O. Box 879801
Tempe, AZ 85287
and NBER
kuminoff@asu.edu

Christopher A. Powers
7500 Security Boulevard
Mailstop B2-29-04
Baltimore, MD 21244
Christopher.Powers@cms.hhs.gov

The classical view of consumer theory maintains that people choose best for themselves. Yet
the notion of consumer sovereignty has long evoked criticism. As early as 1966, George Stigler
wrote that critics â€œsay that people typically do not maximize anythingâ€”that the consumer is lazy
or dominated by advertisers or poor arithmeticâ€ (p.2). Since then, economists have found numerous examples of people leaving money on the table, even when the financial stakes are high, e.g.
enrollment in retirement savings plans (Madrian and Shea 2001), access to credit (Woodward
and Hall 2012, Agarwal and Mazumder 2013), health insurance (Handel 2013) and prescription
drug insurance (Abaluck and Gruber 2011). These results are often interpreted as evidence that
people make choices that do not maximize their own utility. To explain these results, some researchers have applied the framework of Kahneman, Wakker, and Sarin (1997) in which the â€œdecision utilityâ€ (DU) function that guides consumer choice in the marketplace diverges from the
â€œhedonic utilityâ€ (HU) function that measures their satisfaction from consuming the purchased
goods. Perceived divergences between DU and HU are viewed as a rationale for paternalistic
policies intended to increase welfare by guiding people to make better choices, defined as those
that come closer to maximizing HU (Camerer et al. 2003).
One high profile example of this approach is Abaluck and Gruber (2011), henceforth AG.
They sought to evaluate the quality of consumer decision making in the market for prescription
drug insurance plans (PDPs) under Medicare Part D. AG began by showing that, ex post, over
70% of enrollees could have reduced their PDP expenditures without increasing their exposure to
risk. They used this nonparametric evidence to motivate a parametric test of whether peopleâ€™s
PDP choices were consistent with maximizing a particular HU function that depends on PDP
quality in addition to the mean and variance of cost. For the purpose of this test, AG defined the
benchmark HU function as a first-order Taylor approximation to a constant absolute risk aversion model and then used data on consumersâ€™ PDP choices to estimate a linear and additively
separable DU function.1 Differences between the HU and DU functions were interpreted as evidence that consumers â€œsimply errâ€ due to heuristics or â€œlack of cognitive abilityâ€ (p.1209), creating â€œwelfare loss due to consumer mistakesâ€ (p.1194) that could be avoided by policies allowing
â€œless scope for choosing the wrong planâ€ (p.1209). Specifically, AG found that their estimated
DU function violated three restrictions implied by their chosen HU function, which they interpreted as evidence that consumers make three mistakes: (1) they underweight out-of-pocket costs
1

AG refer to DU as the â€œpositive utility functionâ€ and HU as the â€œnormative utility function.â€

1

relative to plan premiums; (2) their choices depend on financial attributes beyond the extent to
which those attributes affect their own costs; and (3) they underweight the variance-reducing aspects of plans. AG used these findingsâ€”along with the additional assumption that econometric
errors in their multinomial logit model represent idiosyncratic mistakes made by consumersâ€”to
conclude that consumer mistakes yielded a welfare loss equivalent to 27% of out-of-pocket expenditures on plan premiums and prescription drugs in 2006. Our replication of their analysis
shows that just over two thirds of this estimated welfare loss is due to AGâ€™s interpretation of the
econometric error terms as consumer mistakes.
In this article we develop a methodology for determining when a structural model of decision
making can be used to infer the quality of consumersâ€™ decisions and use it to assess AGâ€™s conclusions. Our research is motivated by the broad interest in evaluating the quality of consumer
decision making and its implications for welfare, the policy relevance of health insurance market
design, and the challenges inherent in both tasks. In particular, a key challenge with using testable restrictions on parametric models to assess consumer decision making quality is that such
tests conflate two distinct explanations for violations of the parametric restrictions. Varian (1983,
p.99) summarized the issue as follows: â€œThis procedure suffers from the defect that one is always
testing a joint hypothesis: whatever restrictions one wants to test plus the maintained hypothesis
of functional form.â€ This raises the question: do violations of AGâ€™s restrictions reflect optimization mistakes made by consumers; do they represent a rejection of AGâ€™s parametric model for
utility; or some combination of the two? We disentangle these hypotheses and test them separately using five years of administrative data from the Centers for Medicare and Medicaid Services
(CMS).
We begin by adapting Varianâ€™s (1983) nonparametric tests of utility maximization to the PDP
markets from 2006 to 2010. During this period the average consumer chose from more than 40
PDPs that differed in terms of expected cost, variance, and quality. We replicate AGâ€™s nonparametric analysis (based solely on the mean and variance of cost) and then extend their analysis to
recognize that consumers may also care about features of plan quality as in AGâ€™s parametric
model. Like AG, we control for aspects of PDP quality that consumers observe but analysts do
not using the brand name of the firm selling the insurance, so that latent â€œqualityâ€ includes all between-firm differences in PDP attributes besides our measures of mean and variance of ex post
costs. We find that between 2006 and 2010 79% of consumers made PDP choices that were con-

2

sistent with maximizing some utility function satisfying the basic axioms of consumer preference
theory under the assumptions of full information and perfect foresight about future drug needs.2
A potential limitation of our nonparametric test is that it reveals whether choices are consistent with maximizing any utility function that satisfies the basic axioms, even if that implies
extreme tradeoffs between PDP attributes. For example, analysts may find it improbable that the
average consumer would be willing to pay over $1,000 per year for latent features of PDP quality. We address this potential concern by developing a measure of the willingness to pay for firmspecific quality that is sufficient to rationalize the choice made by each consumer. Over our five
year study period the median sufficient willingness to pay is $47, or 4% of out-of-pocket expenditures. We also show that a majority of consumers have the option to choose an inferior PDP offered by their chosen brand and yet most of them avoid doing so. Further, the odds of choosing
an inferior plan decline between 2006 and 2010 despite increasing availability of inferior plans.
In summary, our nonparametric analysis reveals that AGâ€™s evidence of choice inconsistencies is
not robust to alternative specifications for utility. This motivates the need to test the fit and predictive power of their structural model against alternative models that make different predictions
for the welfare effects of paternalistic policies.
When we estimate AGâ€™s multinomial logit model using CMS data we replicate the results that
they interpret as consumer mistakes. However, we also find that AGâ€™s evidence of mistakes persists for the 25% of consumers who chose plans on Lancasterâ€™s (1966) efficient frontier in terms
of cost and variance. We then design and implement three tests of AGâ€™s structural model of PDP
choice.
Our first test estimates AGâ€™s model after adding placebo attributes to each PDP. The results
imply that consumers are willing to pay about as much for the placebo attributes as they are willing to pay for most of the real financial attributes that AG interpret as consumer mistakes. This is
evidence that AGâ€™s parametric test of utility maximization is vulnerable to economically important type I errors. Our second test leverages heterogeneity in the PDP menu across 32 CMS
markets to investigate whether between-market variation in the signs and magnitudes of the
measures that AG interpret as mistakes can be explained by between-market variation in the factors that AG hypothesize to cause mistakes. We find that their measures for mistakes, and the as2

The share of consumers making consistent choices increases if we relax these assumptions to recognize that some consumers are forward looking over multiple years, that consumers differ in the way they form expectations about their future drug needs, or that consumer utility may depend on higher order moments of the distribution of expenditures.

3

sociated welfare losses, often vary by an order of magnitude or more across regions; they also
vary in sign. This variation appears to be unrelated to institutional and demographic factors often
found to be correlated with financial literacy and decision making quality, such as age, dementia,
and the number of choices available. We interpret these results as evidence of potential model
misspecification. Our last test compares the out-of-sample predictive power of AGâ€™s model to
their benchmark model that assumes consumers maximize expected utility. Despite having less
econometric flexibility, the model that assumes people do not make any of AGâ€™s three explicit
mistakes performs about as well, and often better, at predicting how people make choices when
they are faced with different PDP options.
Overall, we find that AGâ€™s evidence of welfare-reducing optimization mistakes is driven primarily by their assumptions about the parametric form of utility and by interpreting econometric
errors as consumer mistakes. Our analysis of the CMS data provides evidence that consumers
pay attention to how the financial attributes of PDPs affect their own costs.3 We also find that a
simpler version of AGâ€™s model that assumes people maximize expected utility often makes better
out-of-sample predictions. While these empirical results do not prove that people always make
fully informed enrollment decisions in Medicare Part D, they do suggest that welfare-reducing
mistakes may not be as large or as widespread as AG concluded.
I.

Testing the Consistency of Consumer Choices in Medicare Part D

In this section we explain key aspects of Medicare Part D and the distinction between parametric and nonparametric tests of utility maximization in a differentiated product market. The
purpose is to provide context for our nonparametric analysis in Sections II and III and our parametric analysis in sections IV and V.
A. A Standard Model of Prescription Drug Plan Choice
The Center for Medicare and Medicaid Services (CMS) divides the nation into 34 regions,
each of which offers a distinct set of PDP options.4 During the annual open enrollment, consumers choose a PDP for the following year. Consider the enrollment period in a single region. Consumers are free to choose among j=1,â€¦,J plans that differ in terms of the premium, ğ‘ğ‘— , and a
The CMS data mitigate measurement errors present in the data used by AG and consequently overturn AGâ€™s finding that consumers ignore the
individual benefits of purchasing gap coverage, which led AG to conclude that â€œindividuals consider plan characteristics in making their choicesâ€”but not how those plan characteristics matter for themselvesâ€ (p 1191).
4
For the list of regions see: http://www.q1medicare.com/PartD-2013MedicarePartDOverview-Region.php.
3

4

vector of variables defining drug costs, ğ‘ğ‘— , that includes the deductible and the price structure for
each available level of coverage. PDPs may also differ in a vector of quality attributes, ğ‘ğ‘— . Examples include customer service, pharmacy networks, the ease of obtaining drugs by mail order
and the presence of supply-side controls such as prior authorization requirements. These characteristics determine the time and effort required for a consumer to obtain her eligible benefits under the plan.
Consumer iâ€™s expenditures under plan j equal the premium plus the out-of-pocket (OOP) costs
of any drugs she purchases. Expenditures can be written as ğ‘ğ‘— + ğ‘œğ‘œğ‘(ğ‘ğ‘— , ğ‘¥ğ‘–ğ‘— ), where ğ‘¥ğ‘–ğ‘— is a vector
of drug quantities. In general, OOP costs are a nonlinear function of drug purchases due to the
plansâ€™ designs. The consumerâ€™s health depends on a random shock, ğ‘¤ğ‘– , that she realizes after
choosing a plan, and on her drug consumption: â„ğ‘–ğ‘— = â„(ğ‘¤ğ‘– , ğ‘¥ğ‘–ğ‘— ). Utility is a function of the consumerâ€™s health, the quality of her PDP, and her consumption of a composite numeraire good, ğ‘šğ‘– .
It is useful to decompose the utility maximization problem into two stages, following Cardon and
Hendel (2001).5 In the first stage the consumer selects a plan, and in the second stage she experiences a health shock and purchases drugs. The second stage problem of optimal drug consumption can be written as:
ğ‘ˆğ‘–ğ‘—âˆ— = ğ‘ˆ âˆ— (â„ğ‘–ğ‘— , ğ‘ğ‘— , ğ‘šğ‘– ) = max ğ‘ˆ[â„(ğ‘¤ğ‘– , ğ‘¥ğ‘–ğ‘— ), ğ‘ğ‘— , ğ‘šğ‘– ]

(1)

ğ‘¥ğ‘–ğ‘—

subject to ğ‘šğ‘– = ğ‘¦ğ‘– âˆ’ ğ‘ğ‘— âˆ’ ğ‘œğ‘œğ‘(ğ‘ğ‘— , ğ‘¥ğ‘–ğ‘— ),

where ğ‘ˆğ‘–ğ‘—âˆ— is the indirect utility that consumer i experiences from plan j at her optimal level of
drug consumption conditional on that plan. Optimal drug consumption may differ from plan to
plan due to variation in drug prices and plan quality.
The consumerâ€™s expected utility from plan j is defined by integrating over her perceived distribution of health shocks, characterized by density function ğ‘“ğ‘– (ğ‘ ğ‘– ).
(2)

ğ‘‰(â„ğ‘–ğ‘— , ğ‘ğ‘— , ğ‘¦ğ‘– âˆ’ ğ‘ğ‘— âˆ’ ğ‘œğ‘œğ‘ğ‘–ğ‘— ) â‰¡ ğ¸(ğ‘ˆğ‘–ğ‘—âˆ— ) = âˆ« ğ‘ˆ âˆ— (â„(ğ‘ ğ‘– , ğ‘¥ğ‘–ğ‘— ), ğ‘ğ‘— , ğ‘šğ‘– )ğ‘“ğ‘– (ğ‘ ğ‘– )ğ‘‘ğ‘ ğ‘– .

Comparing expected utility over the J plans leads to the first stage problem of choosing the utility maximizing plan:

5

Zeckhauser (1970) represents the earliest predecessor known to us. McGuire (2012) follows Goldman and Philipson (2007) with a slightly different approach in which the consumer chooses the level of medical care and an optimal coinsurance rate, where premia are a function of those.
Cardon and Hendelâ€™s approach is also used in Handel (2013) and Einav et al. (2013).

5

(3)

max { ğ‘‰(â„ğ‘–ğ‘— , ğ‘ğ‘— , ğ‘¦ğ‘– âˆ’ ğ‘ğ‘— âˆ’ ğ‘œğ‘œğ‘ğ‘–ğ‘— ) } .
ğ‘—

In principle, each consumerâ€™s PDP choice and subsequent OOP expenditures can be observed,
along with ğ‘ğ‘— , ğ‘ğ‘— , and ğ‘ğ‘— for every plan. The challenge is to use this information to test whether
consumers make choices that are consistent with utility maximization under full information.
B. Parametric and Nonparametric Tests of Utility Maximization
Consistent with Varian (1983), we define a nonparametric test of utility maximization as a
test of whether the data could have been generated by maximizing a utility function that satisfies
basic axioms of consumer theory (e.g. completeness, transitivity, nonsatiation). In contrast, a
parametric test assesses whether the data were generated by maximizing a particular utility function. Both tests require data on every variable that enters the maximization problem in (3). First,
the analyst must make an assumption about which moments of the consumerâ€™s perceived joint
distribution of health outcomes and OOP expenditures enter the indirect utility function in (2).
Second, the analyst must make an assumption about the form of ğ‘“ğ‘– (ğ‘ ğ‘– ) to construct those moments for each of the J available plans.
Given these assumptions and data on every plan, the analyst can nonparametrically test
whether people choose plans that lie on what Lancaster (1966) defined as the â€œefficiency frontierâ€ in characteristics space. A plan is on the frontier if and only if it is not dominated by another
plan on every characteristic. Any choice on the frontier is consistent with the basic axioms of
consumer theory, and any choice off the frontier violates a basic axiom. To conduct a parametric
test, the analyst must further specify the form of utility, and the test results indicate whether consumersâ€™ choices are consistent with maximizing that particular utility function. Hence, parametric and nonparametric tests present a tradeoff between Type I and Type II errors. A nonparametric test that fails to reject the hypothesis of utility maximization may imply that consumers are
willing to make tradeoffs between attributes that some researchers view as too extreme to be
anything other than a mistake. In contrast, a parametric test that rejects the hypothesis of utility
maximization may actually be rejecting the researcherâ€™s assumption for the parametric form of
utility in the sense that consumersâ€™ choices maximize other utility functions with attribute
tradeoffs that researchers or policy makers would view as reasonable.6
6

This assumes the analyst has data on every variable in the maximization problem in (3) and there is no measurement error. Nonparametric tests

6

If model misspecification can be ruled out, then a parametric test would be decisive and the
results could be used to identify mistakes in the choice process and guide welfare-improving policies. The innate inability of any analyst to know the parametric form of consumersâ€™ utility, apart
from revealed preference logic, motivates our research design. First, we use nonparametric tests
to reveal whether the results from a parametric test are idiosyncratic to the analystâ€™s chosen functional form or whether they are robust across the full scope of utility functions that satisfy the axioms of consumer preference theory. Second, we design tests for misspecification of a parametric
model of the choice process.
II. Using CMS Data to Reassess the Facts on Plan Choice
A.

Data on drug plan choice and prescription drug expenditures

We worked with the Centers for Medicare and Medicaid Services (CMS) to obtain data on
Medicare beneficiariesâ€™ demographics, medical conditions, prescription drug use, PDP choices,
and the set of plans available to them. Additionally, we incorporate institutional knowledge from
CMS to develop the best available calculator for the costs each person would have incurred in
each plan that was available to her.7 We begin with a random 20% sample of every Medicare
beneficiary and then impose a few eligibility criteria. Most importantly, we follow AG in limiting our analysis to people who chose a standalone PDP and did not receive a federal low-income
subsidy. Following AGâ€™s methodology, we also excluded those for whom we could not calculate
the plan-specific variance in costs.8
Table 1 summarizes our CMS data on plan spending and compares it to the AG data. The AG
data were obtained from Source Healthcare Analytics (then named Wolters Kluwer Health
(WKH)) which collects data primarily via contracts with pharmacies. The WKH data have two
main limitations for studying PDP choice. First, they do not typically capture all of the prescriptions filled by a given individual in a given year. As a result, the actual average OOP costs
($994) are approximately 50% higher than reported by AG ($666).9 Second, the WKH data do
are only affected by measurement error in the case where the error changes the ordering of goods in attribute space. Parametric tests are more
vulnerable to measurement error due to the cardinal nature of the testing procedure.
7
The â€œcost calculatorâ€ is described in Ketcham, Lucarelli and Powers (2014). The correlation between calculated spending and actual spending
ranges from .92 in 2006 to .98 in 2009. AG do not report comparable statistics for their calculator.
8
We adopt AGâ€™s approach to defining variables except where noted otherwise. Their approach to defining variance was based on grouping people into 1000 different cells based on their prior yearâ€™s total drug spending, daysâ€™ supply of branded drugs, and daysâ€™ supply of generic drugs.
Whereas they used a random sample of 200 people from everyone in their data to define a cellâ€™s variance regardless of region or plan type, we
use the full set of people enrolled in a PDP in the same region.
9
We cannot determine the exact percentage because the WKH data do not identify whether a consumer was enrolled in a PDP for the entire year.
The $995 average cost measure reported for the 2006 CMS data in Table 1 is calculated for consumers who were enrolled the entire year. If we

7

not report which plan each person selects or even whether a person selects a PDP at all. AG attempted to infer each personâ€™s chosen plan based on their OOP costs but found that 50% could
not be matched to any plan and 21% were matched to multiple plans. 10 To overcome this problem, AG randomly assigned people to one of the multiple potential matches with probabilities
chosen to reproduce each planâ€™s national market shares.11 This assignment rule helps to explain
the biases in AGâ€™s data evident from Table 1 and in their findings on gap coverage explained below.
TABLE 1â€”COMPARING CMS AND AG DATA ON PLAN CHOICE, 2006-2010

number of consumers used in estimation
number of plans
number of states
number of contract id's
number of brands
mean age
% female
average premiums ($)
average out-of-pocket costs ($)

AG's data
2006
95,742
702
47
36
75
60
287
666

Our CMS data
2006
2007
2008
2009
2010
479,657 582,619 618,220 630,282 643,335
1,348
1,607
1,719
1,632
1,513
50
50
50
50
50
73
77
78
71
68
69
76
75
71
66
76
76
76
76
76
63
64
63
63
62
362
369
415
487
516
994
892
858
892
886

Note: The table compares summary statistics reported in AG using the Wolters Kluwer Health to our data from Centers for Medicare
and Medicaid Services. We focus on consumers who were enrolled for the entire year, using a 20% sample in 2006 and a 10% sample in 2007-2010.

The final novelty of our data is our approach to defining brands. AG used CMS contract IDs
to create dummies meant to capture unobserved PDP quality. As the name implies, contract IDs
exist for contracting purposes between insurers and CMS; they are not observed by consumers
and in many cases do not match the brand names seen by consumers. Instead, we use company
and plan names to create an alternative set of brand dummies that we expect to be meaningful to
consumers.12

add all the consumers who enrolled for only part of the year, the figure drops to $890. In this article we restrict our attention to people who were
enrolled in a single PDP for the full 12 months, as we expect the choice process may differ for part year enrollees. Excluding them also makes
2006 more comparable to later years, as open enrollment extended through May, creating a large cohort of part-year enrollees for 2006 not found
in other years.
10
This inference is difficult as a drug can have more than 32 different OOP costs within a single PDP because OOP costs can differ with the 4
phases of coverage, pharmacy type, pharmacy network status, quantity dispensed, and other attributes. Due to this complexity, AG assigned a
person to a plan if they could match (defined as a price within 5%) as few as 50% of the personâ€™s observed OOP costs to the formulary of that
plan every month from June 2006 through December 2006.
11
The use of national market shares is problematic because a given planâ€™s market share often varies dramatically across CMS regions due, in part,
to variation in the set of competing plans offered in each region.
12
Both approaches yield approximately the same number of brands in every CMS region and year, as can be seen from Table 1. CMS made company and plan names available to researchers in July, 2014. Table A1 provides an example of how we use these new variables to create brand
dummies that differ from those used by AG. Replacing contract id with our brand dummies increases the pseudo R2 for AGâ€™s parametric model
from 0.32 to 0.37. Some of AGâ€™s key results are sensitive to which brand indicators are used e.g. as evident by comparing the region-specific results in Figures 3 and A3. We report the robustness of our main results to using AGâ€™s dummies in Table A11.

8

B.

Evaluating AGâ€™s Conclusions about Enrollment in Gap Coverage

AG used the choice of plans with gap coverage in 2006 as their leading result in support of
their conclusion that consumers fail to pay proper attention to plan attributes. Specifically, they
observed that â€œthe percentage choosing donut hole coverage is virtually flat throughout the
spending distributionâ€¦[with] the same proportion of individuals in the tenth and eighty-fifth
percentile of the spending distribution choose donut hole [i.e. gap] coverageâ€ (p 1192, emphasis
added). They interpreted the lack of a positive relationship between total spending and enrollment in gap coverage as evidence of consumer mistakes because the expected benefits of gap
coverage are higher for someone in the 85th percentile than in the 10th percentile.13
AGâ€™s evidence of this effect is provided in panel A of Figure 1 (reproduced from AG Figure
3). The horizontal axis measures the quantile of total (OOP plus third party paid) expenditures on
prescription drugs. The right vertical axis measures the â€œcost premiumâ€ for gap coverage, defined by the amount an individual would save by choosing the lowest cost available plan with
gap coverage instead of the lowest cost available plan without gap coverage. The top locus depicts the average cost premium, conditional on drug expenditure quantile. The left vertical axis
and the lower locus indicate the percent of people in each expenditure quantile who choose a
plan with gap coverage. If people were paying attention to plan attributes, preferred lower-cost
plans, and had some foresight about their drug expenditures, then ceteris paribus we would expect the probability of selecting gap coverage to be inversely associated with the cost premium.
The failure to observe such an upward-sloping relationship in panel A is what led AG to conclude that individuals do not consider how plan characteristics influence their own drug expenditures.
The CMS data overturn AGâ€™s finding that consumers failed to consider how gap coverage
mattered for themselves, as shown in Panel B. The probability of selecting gap coverage increases throughout the spending distribution up to the catastrophic coverage limit, and the rate of increase rises in the gap, where the thresholds at which people enter and exit the gap are demarcated by the vertical lines. The probability of selecting gap coverage is strongly, positively
associated with total drug spending and inversely associated with the cost premium. In contrast

13

In 2006, the standard PDP design was required to insure annual prescription drug costs with actuarial equivalence to a schedule that varied with
the beneficiariesâ€™ OOP and gross drug cumulative annual spending. This included no coverage between $2,500 and 5,100 in total (OOP plus insurer-paid) costs. Many insurers deviated from this standard plan and offered â€œenhancedâ€ plans with coverage in the â€œgapâ€ for generic drugs or
generic and brand drugs.

9

to the statistic that AG report, the percentage of people choosing gap coverage at the eighty-fifth
percentile is actually 4 times larger than the percentage at the tenth percentile: 23.3% compared
to 5.7%. This is consistent with people paying attention to the effects of gap coverage on their
own spending because gap coverage saves enrollees an average of $185 at the eighty-fifth percentile and costs them an average of $283 at the tenth percentile. Evaluating the right tail of the
spending distribution in panel B provides further evidence that people are more likely to choose
gap coverage if their cost savings from doing so are higher. For people who exit the gap and enter the catastrophic coverage phase, the cost premium again begins to rise and enrollment in gap
coverage declines.14
A. Gap coverage in 2006: AG

B. Gap coverage in 2006: CMS data

FIGURE 1: PERCENT CHOOSING GAP COVERAGE AND ADDED COST BY EXPENDITURE QUANTILE

Overall, panel B provides evidence that people in fact did consider how gap coverage mattered for themselves in 2006.15 This finding is especially noteworthy because the market was
new. People appear to have anticipated their own future drug consumption and considered how
this peculiar plan attribute, not commonly found in other insurance products, would ultimately
affect their costs.16
Several aspects of AGâ€™s data and methodology may have contributed to their inability to de-

14

We do not know whether AG found the same result because their figure was truncated at the 91.25th percentile. Also in contrast with panel A,
the cost premium declines as expenditures rise. The premium peaks well under $400 at the 0 th percentile, whereas AG indicated that it peaks
above $600 around the 80th percentile. This divergence could be caused by the fact that AGâ€™s cost calculator assumes every drug had a uniform
negotiated price across all plans, whereas the large insurers with popular gap plans, ceteris paribus, would be able to negotiate lower prices for a
given drug.
15
The experiences of insurers provides additional support for this result. Specifically, the largest provider of full gap coverage, Humana, was reported to lose $20 million (33%) on their full gap plan in 2006 due to the heavy use of gap coverage among that plansâ€™ enrollees. As a result of
these losses, for 2007 they withdrew full gap coverage from the market.
16
Figure A1 shows that enrollment in gap coverage increased in regions and years where the benefits from gap coverage were larger. Table A2
shows that similar patterns exist for other plan attributes. For example, enrolleesâ€™ paid $112 below average in OOP costs; they selected a plan
with 17% less variability in OOP spending; and chose a plan with a 6% higher quality rating.

10

tect the positive relationship between the benefits of gap coverage and enrollment in plans with
that coverage. Perhaps the most important derives from the fact that AG could not observe peopleâ€™s actual PDP choices in their data. In the common case that their choice imputation procedure
yielded more than one potentially chosen PDP, AG randomly assigned people to plans with the
probability of assignment chosen to reproduce national market shares. As the CMS data reveal,
the probability of selecting gap coverage is increasing in drug expenditures. Consequently, random assignment would have flattened the curve by placing upward bias on the probability of gap
coverage at low expenditure quantiles and downward bias on the probability of gap coverage at
high expenditure quantiles. In fact, AG noted that their inability to match people to plans was especially severe for Humana (p. 1188), one of the largest providers of gap coverage in 2006 and,
â€œthe insurer that offered the most generous [gap] coverageâ€ (p.1206).17
AG emphasized that failure to find a positive slope in Figure 1A suggests choice inconsistencies. One might also ask whether anything less than full enrollment in gap coverage at expenditure quantiles with a negative cost premium is evidence of choice inconsistencies. Inspecting the
micro data underlying the quantile averages in panel B reveals this is not the case: even among
people who ended the year in the gap, the cost premium for gap coverage is positive for 64%.
Hence if every person chose the plan that minimized their ex post costs, then 36% of people in
the gap would have gap coverage. Looking at the full spending distribution, 14% of people could
have saved more than $100 by switching into or out of gap coverage (9.9% by switching to a
plan with gap and 4.2% by switching to a plan without gap). Raising the threshold to $300 lowers these percentages to 6.5% and 1.1%, respectively; raising it to $750 lowers them to 2.5% and
0.0%.18 Uncertainty about future drug consumption provides a potential explanation for why
people left money on the table on the basis of this metric, which relies on ex post drug consumption to define the cost premium. The extent to which gap coverage raises or lowers an individualâ€™s costs can vary widely over small movements in the ex post spending distribution around the
gap and catastrophic thresholds, as can be seen from the quantile averages in the figure. Furthermore, the analysis in Figure 1 is unconditional on plan variance and quality. For example,
17

Many states provide subsidies to populations that do not qualify for the federal low income subsidies. Individual use of these subsidies is not
recorded in CMS or WKH data. The following states did not offer these programs from 2006-2010: AL, AR, CO, FL, GA, IA, ID, KS, KY, MI,
MN, MS, NE, NH, SC, SD, TN, TX, UT, VA, WV, WY. When we reproduce Figure 1.B using only these states the share of consumers enrolled
in gap coverage at the 85th percentile of the expenditure distribution is more than 5 times as large as the share at the 10 th percentile (27% compared to 5%). This provides further evidence that people pay attention to how gap coverage benefits themselves as the benefits are smaller in
states with these subsidies in ways not incorporated into the CMS data, the cost calculator or the gap cost premium.
18
Table A3 provides results from additional thresholds in 2006 and 2007. The results show that the share with potential savings at these thresholds in 2007 was about half the share in 2006.

11

among the 4.2% who chose a gap plan but could have saved at least $100 by choosing a non-gap
plan, the gap plan may maximize utility through its ability to reduce variance or through any other features of plan quality provided by plans with gap coverage. Our nonparametric tests reveal
the extent to which the data are consistent with this explanation.
III. Nonparametric Tests of Consistency with Utility Maximization
The generalized axiom of revealed preference (GARP) is often used to test whether data are
consistent with utility maximization. However GARP is not directly applicable to PDP choice
because consumers are not free to choose continuous combinations of plan characteristics and
the budget constraint is nonlinear.19 Nevertheless, similar axioms imply that a utility maximizing
consumer will choose a plan that lies on Lancasterâ€™s (1966) efficiency frontier. Suppose a consumer is risk averse and has preferences that are complete, transitive, and strongly monotonic
over the attributes of PDPs.20 Under these mild restrictions, optimization under full information
implies the consumer will never choose a plan, k, that lies below the frontier in the sense that
when we compare it to another feasible plan, j, plan k has: (i) equal or higher expected OOP
costs, (ii) equal or more variable OOP costs; (iii) equal or lower values for every dimension of
perceived plan quality; and (iv) at least one of these inequalities is strict. In this case plan j dominates plan k for any utility maximizing consumer. Therefore, calculating the share of people who
choose dominated plans provides a nonparametric test of choice consistency that is robust to any
utility function satisfying completeness, transitivity, and strong monotonicity. These mild restrictions are consistent with a broad class of preferences that allow utility to be nonlinear and
nonseparable in plan attributes. They also allow for flexible forms of heterogeneity in risk aversion and in relative preferences for plan quality. For example, a utility maximizing consumer
with strong preferences for more extensive formulary coverage may choose a plan offered by an
insurer that places fewer restrictions on drugs, even if our measures of the mean and variance of
ex posts costs are higher under that insurerâ€™s plans.
Table 2 reports the share of people choosing plans on the efficiency frontier each year from
2006 through 2010. As we move from row 1 to row 5 we expand the set of attributes assumed to

19

See Kariv and Silverman (2013) for an overview of the challenges in testing whether data are consistent with utility maximization when consumers are free to choose continuous bundles of homogeneous goods with linear budget constraints.
20
Completeness says that consumers can compare any two plans. Transitivity says that if plan A is preferred to plan B, and plan B is preferred to
plan C, then plan A must be preferred to plan C. Strong monotonicity says that, all else constant, consumers prefer plans with more of any positive attribute.

12

enter utility. We start in row 1 with the naÃ¯ve assumption that mean ex post cost is the only attribute that people value. Specifically, we follow AGâ€™s assumption that consumers should have
perfect foresight on their future drug needs and set ğ¸(ğ‘œğ‘œğ‘ğ‘–ğ‘— ) for year t equal to plan jâ€™s cost of
purchasing the drugs that consumer i actually purchased that year. The share of people choosing
frontier plans in this single dimension ranges from 6% to 10% each year. In row 2 we add
ğ‘£ğ‘ğ‘Ÿ(ğ‘œğ‘œğ‘ğ‘–ğ‘— ). Accounting for the variance raises the fraction of people on the frontier to between
24% and 36%. The fraction in 2006 is 25%, just below the 30% reported by AG. Importantly,
this is where AG stopped testing.
Row 3 adds an index of overall plan quality developed by CMS.21 This raises the share of
people choosing frontier plans to 33% to 46%. Row 4 replaces the CMS index with brand dummies, just as AG do in their parametric model.22 The difference is that the nonparametric test allows people to have heterogeneous preferences for unobserved features of PDP quality that vary
from brand to brand.23 When we add these dummies, 73% to 82% of choices are consistent with
maximizing a well behaved utility function. The share of people choosing frontier plans increases further if we allow utility to depend on higher order moments of the OOP distribution, if we
allow the demand for drugs to be less than perfectly inelastic, if we introduce forward looking
behavior and switching costs, or if we allow for heterogeneity in expectations. Row 5 illustrates
this point by relaxing the assumption that every person knows their future drug consumption.
Some people may expect their future drug consumption to be the same as their past consumption,
for example. We allow this possibility by calculating two separate measures of ğ¸(ğ‘œğ‘œğ‘ğ‘–ğ‘— )â€”one
based on the personâ€™s drug consumption in year t and one based on her consumption in year t-1.
Adding both variables to the utility function recognizes that uncertainty about drug consumption
may cause a personâ€™s expectations to be a weighted average of these two cases. 24 This further increases the rate of consistent choices to as high as 89% in 2009.25

21

CMS did not construct the quality index for 2006. AG used the 2008 CMS quality index for 2006. We use 2007 ratings, the earliest available,
for 2006. We use updated ratings for each subsequent year, e.g. the 2008 ratings are used for 2008.
22
The CMS quality index is essentially redundant at this point because there is minimal variation across plans within a brand for a given year.
Adding it as an additional attribute to rows 4 and 5 has virtually no effect on the results.
23
Appendix Table A4 shows that the results are very similar if we follow AG in using contract IDâ€™s to define brand.
24
Formally, define consumer iâ€™s expected OOP costs for plan j during year t at the time of enrollment as ğ¸[ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘—ğ‘¡ ] = ğ›¼ğ‘– ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘—ğ‘¡ + (1 âˆ’
ğ›¼ğ‘– )ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘—ğ‘¡âˆ’1 , where ğ›¼ğ‘– is between 0 and 1. When we admit that we do not know ğ›¼ğ‘– , we cannot conclude that plan j dominates plan k unless
ğ¸[ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘—ğ‘¡ ] < ğ¸[ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘˜ğ‘¡ ] for every feasible value of ğ›¼ğ‘– . Therefore, plan k is only dominated if ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘—ğ‘¡ < ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘˜ğ‘¡ and ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘—ğ‘¡âˆ’1 < ğ‘‚ğ‘‚ğ‘ƒğ‘–ğ‘˜ğ‘¡âˆ’1 .
25
We cannot perform this test for 2006 because we do not have data on drug consumption for 2005.

13

TABLE 2â€”NONPARAMETRIC TEST OF CHOICE CONSISTENCY

(1)
(2)
(3)
(4)
(5)

Plan attributes affecting utility

Assumption on expected
drug expenditures in year t

E[cost]

year t drug consumption

E[cost], var(cost)

year t drug consumption

E[cost], var(cost), CMS quality

year t drug consumption

E[cost], var(cost), brand

year t drug consumption

E[cost], var(cost), brand

year t or t-1 drug consumption

% Consumers choosing frontier plans
2006

2007

2008

2009

7
25
35
80

7
24
33
73
80

10
24
46
79
86

6
26
42
82
89

2010 2006-2010
8
36
45
82
87

8
27
41
79
86

Note: The table reports the share of people choosing undominated plans on their efficiency frontier as a function of plan attributes and modeling
assumptions. See the text for details.

Table 2 reveals that understanding the roles of PDP attributes captured by the brand dummy
variables is essential to determining whether most people are making choices that are consistent
with expected utility maximization. This raises three questions. First, is it plausible for people to
have heterogeneous brand preferences? We think the answer is yes. Brands differ in their formulary design for specific drugs in ways not reflected in our measures of mean and variance of ex
post OOP costs. For example, brands with high cost sharing (e.g. high copays or lack of coverage
altogether) on certain drugs may be unattractive to people who have a high likelihood of purchasing those drugs and irrelevant to people who do not. These aspects are not fully captured by
the measured mean and variance of ex post costs. Likewise brands differ in their reliance on supply-side controls such as prior authorization and â€œfail firstâ€ requirements, which are also not incorporated into the mean and variance of ex post costs. Brands also differ in terms of customer
service, ease of obtaining drugs by mail order and pharmacy networks. Each of these differences
has heterogeneous effects across consumers that cannot be captured by CMSâ€™s homogenous star
ratings.26 People also differ in their past experiences with particular insurance companies, e.g.
while they were covered through their employer prior to age 65. In fact, when Medicare beneficiaries were asked about the factors affecting their choice of PDP in a 2006 survey 90% of respondents stated that company reputation was â€œimportantâ€ or â€œvery importantâ€ to their choice
(MedPAC 2006). Other factors that respondents commonly identified as important or very important included having a preferred pharmacy in the planâ€™s network (84%) and signing up with
the same company as a spouse (42%). These factors vary across brands and people, but not
across plans within a brand, making brand dummies the natural proxy measure of these horizontally differentiated attributes.
26

Furthermore, CMS did not assign star ratings until 2007 so this information would not have been available to enrollees during the 2006 enrollment cycle.

14

Second, what causes the share of people choosing plans on the efficiency frontier to rise when
brand dummies are added in row 4 of Table 2? The first mechanism is the quality of decision
making. Each year, the majority of people (52% in 2006 and 72- 79% in later years) had the opportunity to choose a plan offered by their chosen brand that was dominated in terms of mean
and variance of ex post cost. The first two bars within each year in Figure 2 summarize their actual choices: the first bar reports the share of people who chose dominated plans; the second bar
reports the share of people who avoided doing so and chose a frontier plan. Comparing the relative sizes of the two groups across years reveals that the odds of avoiding dominated plans increased over time. Among those offered a dominated plan, the share choosing a plan on their
frontiers climbed steadily from 62% in 2006 to 77% in 2010. To put both the levels and trends in
perspective, if these people had chosen randomly within their chosen brand then the percent of
them in a frontier plan would have been 54%, 59%, 59%, 56% and 54% for 2006-2010 respectively.27 That said, random choice does not represent a lower-bound. If consumersâ€™ choices embed biases and sophisticated firms design products to profit from those biases (Gabaix and
Laibson 2006, Spiegler 2011, Miravete 2013), then we might expect consumers to do worse than
random, not better as shown in the data.

FIGURE 2: CONSUMERS GROUPED BY THE OPPORTUNITY TO CHOOSE A DOMINATED PLAN

27

The improvement is similar when we focus on 66-year olds who are making their first full-year PDP choice and are therefore less susceptible to
any state dependence. Hence, the improvement in choice quality over time is at least partly driven by active choices.

15

The second mechanism is the lack of opportunity to choose a dominated plan. The last group
in Figure 2 includes people whose chosen brand does not offer them a dominated plan. After
2006, the share of people in this group ranged from 21-28%. Their brands offer either a single
plan or multiple plans on the personâ€™s frontier, e.g. one low-cost, high-variance plan and one
high-cost, low-variance plan. If consumer utility depends on horizontally differentiated attributes
that are captured by the brand indicators then these peoplesâ€™ choices are de facto consistent with
maximizing utility functions that satisfy the basic axioms.
The fact that we can explain most consumersâ€™ PDP choices as reflecting preferences for latent
features of PDP quality that vary from brand to brand raises a final question. Are the brand preferences required to rationalize choices so large that we should view them as evidence of mistakes? Analysts may wish to move away from testing for consistency of choices with the axioms
of consumer theory and instead place an upper bound on how much a fully informed utilitymaximizing consumer would be willing to pay for unobserved features of PDP quality associated
with their preferred brand. To investigate how such thresholds affect the results, we calculate the
willingness to pay for all between-brand differences besides measured mean and variance of ex
post costs that would be sufficient for a consumerâ€™s PDP choice to maximize a utility function
that satisfies the basic axioms. This measure of â€œsufficient willingness to payâ€ (SWTP) is defined as the cost of the consumerâ€™s chosen plan less the highest-cost plan on the portion of her
cost-variance frontier that dominates her chosen plan.28 Intuitively, SWTP is the amount of money that a person leaves on the table by choosing a plan off the cost-variance frontier.
TABLE 3â€”SUFFICIENT WILLINGNESS TO PAY FOR BRAND
2006

2007

2008

2009

2010

2006 - 2010

All consumers

median SWTP for brand ($)
percent of consumers with SWTP > $500
percent of consumers with SWTP > $1,000
percent of all consumers
mean SWTP for brand ($)
median SWTP for brand ($)

80

44

81

41

26

47

7.3

2.2

2.1

1.2

2.0

2.4

1.6

0.6

0.1

0.1

0.2

0.4

Consumers off the cost-var frontier, but on the cost-var-brand frontier
56
49
55
55
47
52
232

126

169

116

139

147

129

65

136

75

85

89

Note: The table reports the willingness to pay for brand that is sufficient for consumersâ€™ PDP choices to maximize a utility function that satisfies
the basic axioms of consumer preference theory. See the text and appendix for details.

28

The appendix includes a diagram of the SWTP calculation (Figure A2). This is the minimum WTP to trade the bundle of all omitted PDP attributes of the most expensive plan on the segment of the cost-variance frontier that dominates the chosen brand for the bundle provided by the
chosen brand. Central to the logic of this statistic is the fact that by definition, choice of any plan on the frontier is a consistent choice.

16

Table 3 summarizes the SWTP distribution. When we pool the data over all consumers and
years, the median SWTP for brand is $47, or 4% of total expenditures. 29 The last three rows
show results for people who chose a plan off their cost-variance frontier but on their costvariance-brand frontier; i.e. the people who are added when we move from row 2 to row 4 in Table 2. Their mean SWTP is $232 in 2006 and it ranges from $116 to $169 thereafter. These
means are heavily affected by small shares of consumers who exceed the $500 and $1,000
thresholds in the second and third rows of the table. Annual median SWTP ranges from $65 to
$136. Although interpretations may differ, we find it plausible that informed consumers would
be willing to pay these amounts for the bundle of unobserved PDP attributes that differ between
brands.30
In summary, during the first five years of Medicare Part D, 79% of consumers made choices
consistent with maximizing some well-behaved utility function that depends on the mean and
variance of ex post cost and all other attributes that differ between brands. These results suggest
that AGâ€™s parametric evidence of choice inconsistency is primarily driven by their assumptions
about the parametric form of the representative consumerâ€™s utility function.
IV. Using CMS Data to Replicate and Extend AGâ€™s Main Results
A. Replication of AGâ€™s Main Parametric Results and Further Analysis
AG assume that consumersâ€™ decision utility (DU) function is a first order Taylor approximation to a CARA model that is linear and additively separable in plan characteristics,
(4)

ğ·ğ‘ˆğ‘–ğ‘— = ğ‘ğ‘— ğ›¼ + ğœ‡ğ‘–ğ‘— ğ›½1 + ğœğ‘–ğ‘—2 ğ›½2 + ğ‘ğ‘— ğ›½3 + ğ‘ğ‘— ğ›¾ + ğœ–ğ‘–ğ‘— ,

where ğ‘ğ‘— is the plan premium, ğœ‡ğ‘–ğ‘— = ğ¸(ğ‘œğ‘œğ‘ğ‘–ğ‘— ), ğœğ‘–ğ‘—2 = ğ‘£ğ‘ğ‘Ÿ(ğ‘œğ‘œğ‘ğ‘–ğ‘— ), ğ‘ğ‘— is a vector of quality variables
(CMS quality index or brand dummies), and ğ‘ğ‘— is a vector of financial plan characteristics that directly affect ğ‘œğ‘œğ‘ğ‘–ğ‘— . This includes the plan deductible, an indicator for whether the plan provides
full coverage of brand name drugs in the gap, an indicator for whether the plan only covers generic drugs in the gap, a count of the top 100 drugs covered by the plan, and a cost sharing index

29

This includes 21% of consumers whose chosen plans are dominated by another plan within their chosen brand by treating their SWTP as infinite. If we instead focus on the 79% of consumers who choose plans on their cost-variance-brand efficiency frontier (i.e. the consumers represented by the second and third bars in Figure 2) then the median SWTP is $32 or 3% of expenditures.
30
Researchers can also calculate SWTP under stronger restrictions on the shape of the utility function. For example, if we assume that utility is
separable in the omitted variables captured by the brand indicators, then SWTP can be measured by the amount of money that would be saved by
switching to the least expensive plan on the portion of the cost variance frontier that dominates the chosen brand. Adding the separability assumption causes the median SWTP to increase from $47 to $138 and the share with SWTP over $1000 to increase from 0.4% to 0.9%.

17

that measures the average percentage of expenditures covered by the plan between the deductible
and the gap. Finally, ğœ–ğ‘–ğ‘— is a random person-plan specific shock that is assumed to be drawn from
a type I extreme value distribution.
TABLE 4â€” REPLICATION OF AG AND SENSITIVITY TO ALTERNATIVE SPECIFICATIONS
(1)

(2)

(3)

(4)

(5)

Premium [hundreds]

-0.499
(-0.006)***

-0.562
(0.002)***

-0.402
(0.002)***

-0.099
(0.001)***

-0.620
(0.007)***

OOP costs [hundreds]

-0.096
(-0.002)***

-0.102
(0.001)***

-0.108
(0.001)***

-0.099
(0.001)***

-0.410
(0.002)***

Variance (millions)

âˆ’0.0006
(0.0010)

-0.00005
(0.000)

-0.0001
(0.000)

-0.00001
(0.000)

-0.001
(0.000)***

Deductible (hundreds)

-0.163
(0.0070)

-0.020
(0.003)***

0.051
(0.003)***

0.180
(0.008)***

full gap coverage

1.762
(0.0280)

1.909
(0.015)***

1.162
(0.015)***

1.649
(0.038)***

generic gap coverage

0.300
(0.0180)

0.533
(0.009)***

0.356
(0.009)***

0.727
(0.029)***

Cost sharing

1.189
(0.0740)

-0.334
(0.025)***

0.683
(0.024)***

-1.987
(0.090)***

Number of top 100 drugs on formulary

0.059
(0.0020)

0.190
(0.002)***

0.175
(0.001)***

0.386
(0.008)***

Brand definition
Pseudo R

2

number of consumers
Consumers on the cost-variance frontier

contract id

contract id brand name brand name brand name

--

0.32

0.37

0.36

0.60

95,742

464,543

464,543

464,543

117,078

30%

25%

25%

25%

100%

27.0
--

27.8
9.2

38.9
7.4

139.5
0.0

23.4
10.0

Expected welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

Note: Column 1 is copied directly from column 3 of AGâ€™s Table 1. Column 2 reports results from estimating the same econometric specification
using our CMS data. Column 3 replicates the model but uses company and plan names instead of contract IDs to define the brand dummies. Column 4 shows results from a model that requires each of AGâ€™s parametric restrictions be met. Column 5 repeats column 3 but on the subset of consumers that chose a plan on their cost-variance frontier. *** Significant at the 1% level.** Significant at the 5% level. * Significant at the 10%
level.

AG rely on revealed preference logic to interpret their estimate for âˆ’ğ›¼ as the marginal utility
of income and their estimate for ğ›¾ as the marginal utility from plan quality. In contrast, they rely
on their assumption for the hedonic utility (HU) function to define appropriate values for the ğ›½
parameters: (1) ğ›½1 = ğ›¼Ì‚ because consumers should assign equal weight to premiums and expected
OOP costs; (2) ğ›½2 < 0 because consumers should be risk averse; and (3) ğ›½3 = 0 because financial
attributes have no direct effect on HU under AGâ€™s assumption that ğœ‡ğ‘–ğ‘— and ğœğ‘–ğ‘—2 are the only mo-

18

ments of the ex post cost distribution that consumers should care about. AG interpret violations
of these restrictions as evidence that consumers made optimization mistakes, as opposed to evidence of omitted variables, model misspecification, measurement error, or finite sample bias.
We replicate AGâ€™s model (AG Table 1 column 3) using our CMS data for 2006. Table 4 reports AGâ€™s estimates in column 1 and our estimates for their model in column 2. Comparing the
two columns illustrates that we reproduce AGâ€™s three main findings: (i) the coefficient on premium is approximately five times larger than the coefficient on OOP costs; (ii) the negative coefficient on variance is statistically insignificant; and (iii) coefficients on financial characteristics,
such as gap coverage, are nonzero.31 Column 3 is the same as column 2 except that we replace
AGâ€™s indicators for PDP contract id with indicators based on the brand name visible to consumers.32 This increases the pseudo R2 and reduces the premium-to-OOP ratio from 5.5 to 3.7. It also
changes the signs on two of the five financial variables.
B. Replication of AGâ€™s Welfare Calculations and Further Analysis
In the second to last row of Table 4, we replicate AGâ€™s calculation of the partial equilibrium
welfare gain from a hypothetical intervention â€œthat would make individuals full informed and
fully rationalâ€ (p. 1208). For the purpose of estimating welfare losses AG assume that consumersâ€™ HU function is
(5)

ğ»ğ‘ˆğ‘–ğ‘— = (ğ‘ğ‘— + ğœ‡ğ‘–ğ‘— )ğ›¼Ì‚ + ğœğ‘–ğ‘—2 ğ›½Ìƒ2 + ğ‘ğ‘— ğ›¾Ì‚,

where ğ›¼Ì‚ and ğ›¾Ì‚ are estimates from a logit model of equation (4) and the coefficient on variance ğ›½Ìƒ2
is chosen to produce a coefficient of absolute risk aversion of 0.0003 as in AG (p.1208). Welfare
is calculated by using (5) to measure the compensating variation generated by switching from the
plan that maximizes each consumerâ€™s DU function in (4) to the plan that maximizes the HU
function in (5) that AG have chosen for that consumer. The calculation is explained in our appendix. The most important detail is that AG assume that the Type I EV errors in (4) do not enter
the HU function in (5). That is, AG interpret nonzero values for ğœ€ğ‘–ğ‘— as idiosyncratic optimization
mistakes made by consumers.33
Appendix Table A5 demonstrates that we also replicate the pattern of results in AGâ€™s more parsimonious specifications.
Appendix Table A6 reports the results from the model in column 3 separately by year for 2006-2010. Table A7 shows that the premium-to-oop
coefficient ratio in AGâ€™s most parsimonious specification is close to 1 in 2008-2010.
33
AG refer readers seeking an explanation of their welfare calculations to Appendix D of the earlier NBER version of their paper. That appendix
includes the ğœ€ğ‘–ğ‘— â‰¡ 0 assumption and the body of their NBER paper reports the same 27% welfare loss. Abaluck and Gruber (2013) make the same
assumption that ğœ€ğ‘–ğ‘— â‰¡ 0.
31
32

19

To illustrate how AGâ€™s interpretation of ğœ€ğ‘–ğ‘— affects their welfare measure, the last row of Table 4 reports the welfare loss under the common interpretation of ğœ€Ì‚ğ‘–ğ‘— as a combination of misspecification, measurement error, and tastes for unobserved product attributes, in which case ğœ€Ì‚ğ‘–ğ‘—
is assumed to enter HU. This calculation isolates the expected welfare loss from the three mistakes that AG emphasize. The difference between the last two rows isolates the component of the
welfare loss due to AGâ€™s assumption that ğœ€Ì‚ğ‘–ğ‘— represents consumer mistakes. When we set ğœ€ğ‘–ğ‘— â‰¡ 0
in our replication of AGâ€™s model in column 2, the average welfare loss is within one percentage
point of the statistic they report: 27% of plan costs ($366). In contrast, when we allow ğœ€Ì‚ğ‘–ğ‘— to enter utility the average welfare loss declines to 9% of plan costs, or $125 per person per year.
Hence, approximately two thirds of the welfare loss that AG report is due to their assumption
that ğœ€Ì‚ğ‘–ğ‘— represents consumer mistakes. The share due to ğœ€Ì‚ğ‘–ğ‘— rises to 81% in column 3 when we
replace the contract id dummies used by AG with dummies for the insurance brand names seen
by consumers.
In a wide variety of empirical contexts, logit models require ğœ€Ì‚ğ‘–ğ‘— â‰  0 for some consumersâ€™ observed choices to maximize the analystâ€™s specification for utility (e.g. the markets for cars, houses, labor, health care). The decision to interpret ğœ€Ì‚ğ‘–ğ‘— â‰  0 as an optimization mistake in these cases
predetermines that, all else constant, the average consumer will be found to make welfarereducing mistakes. For example, in column 4 we estimate equation (5) after adding an error term.
Despite this model precluding all three of AGâ€™s explicit consumer mistakes, the model still generates large losses under AGâ€™s welfare measure due to nonzero values of ğœ€Ì‚ğ‘–ğ‘— .34
C. Testing Consistency between Parametric and Nonparametric Results
To further investigate how assumptions about the shape of utility affect conclusions about
choice inconsistencies, we estimate AGâ€™s model on the 25% of people who chose plans on their
efficiency frontiers in cost-variance space. By definition, these choices are consistent with minimizing costs or with people maximizing utility by â€œchoosing plans with higher mean expenditure
to protect themselves against variance in expenditureâ€ (AG p.1190). As shown in the last column
of Table 4, AGâ€™s model and welfare measure continues to produce evidence of choice inconsist-

34

The average welfare loss is larger in column 4 than in columns 1-3 primarily because the premium coefficient becomes smaller when we impose AGâ€™s constraints. The results also show that allowing the model to incorporate AGâ€™s three explicit consumer mistakes only improves model
fit marginally, increasing the pseudo R2 from 0.36 to 0.37.

20

encies. While the variance coefficient is negative and significant, the premium-to-OOP coefficient ratio still exceeds one (1.5) and all of the coefficients on financial plan attributes are still
nonzero. Moreover, the welfare loss from these violations (10% of costs) is about as large as our
estimates for the full sample in column 3. This shows that AGâ€™s evidence of welfare reducing
mistakes is primarily identified by their assumption about the parametric form of utility, not by
consumers making inconsistent choices by choosing plans off the efficiency frontier in costvariance space.
D. Caveats to Parametric Tests of Utility Maximization
The research design that AG use to test whether consumers make welfare-reducing mistakes
relies on two general principles. First, there can be no omitted variables. AG addressed this by
stating, â€œwe observe and include in our model all of the publicly available information that might
be used by individuals to make their choicesâ€ (p.1194). Second, the analyst must know the true
parametric forms of consumersâ€™ utility functions. AG addressed the possibility that their model
could be misspecified by noting that two of their results are robust to several alternate specifications. They report 17 sets of estimates in their paper, describe robustness checks not shown in the
paper, and devote an appendix to exploring other utility functions (e.g. CRRA vs. CARA). Nevertheless, these exercises do not validate AGâ€™s methodology for identifying choice inconsistencies: AGâ€™s 17+ specifications represent what Leamer (1983 p. 38) calls a â€œzero volume set in the
space of assumptions.â€ In other words, AGâ€™s robustness checks collectively represent an infinitesimally small share of the specifications for utility that are consistent with basic axioms of consumer preference theory. Of course, models are meant to abstract from reality. Our point is not
that AGâ€™s model is less than perfect. Our point is that omitted variables, measurement error and
misspecification of consumersâ€™ utility functions can be easily misinterpreted as optimization mistakes when common positive models are instead used as normative benchmarks as in AG. Hence
a critical step in relying on this approach to assess the quality of consumer decision making is to
test the validity of the chosen parametric specification.
V. Testing Parametric Specifications for Utility
Let ğ›½ denote a parameter vector satisfying AGâ€™s restrictions on HU in (5): ğ›½ = [ğ›½1 , ğ›½2 , ğ›½3 ]
and let ğ›½Ì‚ğ‘¢ denote an unrestricted estimate for ğ›½ from AGâ€™s DU function in (4) for consumers in

21

market u. The difference between the two vectors can be written as
ğ›½Ì‚ğ‘¢ âˆ’ ğ›½ = ğ‘“(ğ‘”(ğ‘§ğ‘¢ , ğ‘ğ‘¢ ), ğœ‰ğ‘¢ ),

(6)

where the hat indicates that ğ›½Ì‚ğ‘¢ is unrestricted and ğ‘“(âˆ™) is a vector of functions. The sub-function
ğ‘”(ğ‘§ğ‘¢ , ğ‘ğ‘¢ ) is a â€œconsumer mistake functionâ€ that explains how optimization mistakes are caused
by the two mechanisms that AG emphasize: complexity of the PDP menu, described by ğ‘§ğ‘¢ , and
the distribution of cognitive ability among consumers in the market, described by ğ‘ğ‘¢ (AG p.
1183-1184, 1209). The last term inside ğ‘“(âˆ™) represents misspecification of the DU function, ğœ‰ğ‘¢ .
By attributing the difference between ğ›½Ì‚ğ‘¢ and ğ›½ to consumer mistakes, AG implicitly assume that
ğœ‰ğ‘¢ = 0. Our concern is that the difference between ğ›½Ì‚ğ‘¢ and ğ›½ could instead be caused by model
misspecification.35 Therefore, we design three ways to test the hypothesis that ğœ‰ğ‘¢ = 0.
A. Test 1: Do Placebo Characteristics Appear to Affect Consumersâ€™ Decisions?
Our first test is a falsification test of AGâ€™s finding that consumers mistakenly allow redundant
financial plan characteristics to affect their enrollment decisions. AGâ€™s interpretation of the nonzero coefficients on financial characteristics in the logit model as evidence of consumer mistakes
is based on their assertion that their models have no omitted variables (p.1194). Our concern is
that despite AGâ€™s best efforts, and the improvements we have made to the data, the estimated effects of the financial characteristics may still be driven by correlation with omitted measures of
PDP cost, risk protection, and quality.
To provide an opportunity to falsify this hypothesis we replace ğ‘ğ‘— in equation (4) with ğ‘Ìƒğ‘— ,
where ğ‘Ìƒğ‘— = [ğ‘ğ‘— , ğ‘ğ‘™ğ‘ğ‘ğ‘’ğ‘ğ‘œğ‘— ]. Ideally, the placebos should be correlated with premia and OOP
spending, just like the financial characteristics in ğ‘ğ‘— . Unlike ğ‘ğ‘— , the placebos cannot be observed
by consumers so that ğ‘ğ‘™ğ‘ğ‘ğ‘’ğ‘ğ‘œğ‘— cannot directly affect consumersâ€™ choices. Under these conditions, the following restriction should hold:
(7)

ğ›½Ì‚4,ğ‘¢ â„ğ›¼Ì‚ğ‘¢ = 0 âˆ€ ğ‘¢,

where ğ›½Ì‚4,ğ‘¢ is the estimated coefficient on ğ‘ğ‘™ğ‘ğ‘ğ‘’ğ‘ğ‘œğ‘— . A violation of this restriction would be evidence that the model is misspecified in ways that make it vulnerable to finding evidence of consumer biases where none exist.
35

Given the large size of our CMS sample, we abstract from the potential effects of finite sample bias.

22

We create placebos from each planâ€™s three digit identifier (ID). These IDs were developed by
the CMS contractor BUC-CANEER using an encryption process. The IDs vary across plans and
brands but are themselves meaningless and not seen by consumers. The full set of characters in
the IDs is {8, 9, D, d, e, k, l, o, r, x}. Each character can appear up to three times in an ID code.
Our placebos are counts of the number of times each character appears in each planâ€™s ID. Like
the financial characteristics, the placebos are mildly correlated with premia and OOP costs because they and the encrypted ID codes all vary systematically across plans and brands. For example, the correlation between OOP cost and full gap coverage is -0.05 compared to 0.04 for
OOP cost and x-count and -0.01 for OOP cost and r-count.36 Finding that the coefficients on xcount and r-count are zero would build confidence in AGâ€™s conclusion that consumersâ€™ choices
are in fact influenced by financial attributes.
Adding full gap coverage

$306

Replacing two "r"s in the encrypted plan id code with two "x"s

$106

Replacing two "k"s in the encrypted plan id code with two "x"s

$100

Increasing cost sharing from 25% to 65%

$95

Adding generic gap coverage

$89

Replacing two "x"s in the encrypted plan id code with two "d"s

$74

Replacing two "x"s in the encrypted plan id code with two "e"s

$43

Covering one additional "top 100" drug

$40

Replacing two "o"s in the encrypted plan id code with two "x"s

$24

Replacing two "9"s in the encrypted plan id code with two "x"s

$24

Decreasing the deductible from $250 to $0

$15

Replacing two "x"s in the encrypted plan id code with two "l"s

$14

Replacing two "8"s in the encrypted plan id code with two "x"s

$11

Replacing two "D"s in the encrypted plan id code with two "x"s

$7

$0

$100

$200

$300

FIGURE 3: IMPLIED WILLINGNESS TO PAY FOR FINANCIAL AND PLACEBO PLAN ATTRIBUTES

Our estimates for ğ›½Ì‚4,ğ‘¢ â„ğ›¼Ì‚ğ‘¢ are statistically different from zero for every alphanumeric character.37 We assess economic significance by calculating the WTP for changes in the financial and
placebo attributes in 2006 using the same measures of WTP reported by AG (p.1198). To remain
in-sample, we calculate the WTP for replacing two of one character with two of another, yielding
WTP measures that are comparable to AGâ€™s measures of WTP for non-marginal changes in financial attributes. Under the hypothesis that AGâ€™s model is correctly specified the implied WTP
for placebos should be closer to zero than the WTP for real financial attributes. Yet this is not the
case. Figure 3 shows that all but one of the financial attributes have WTP measures that are ex36
37

We report correlation coefficients in appendix Table A8.
The model results are reported in Appendix Table A9.

23

ceeded by WTP for some of the placebos. For example, the DU coefficients imply that consumers are willing to pay $106 to replace two râ€™s with two xâ€™s in the plan ID. This measure is 20%
larger than the implied WTP for generic gap coverage and seven times larger than the WTP for
decreasing the deductible from $250 to $0. AGâ€™s model implies similarly large WTP measures
for substitution patterns of other placebo attributes besides râ€™s and xâ€™s.38 These results show that
consumersâ€™ PDP choices appear to be influenced by fake plan attributes in an economically significant way, with magnitudes similar to the WTP measures for real financial attributes.39 This
falsification test casts doubt on whether consumers are really making PDP choices based on a
planâ€™s cost sharing, generic gap coverage, coverage of the top 100 drugs, and deductible.40
B. Test 2: Are the Utility Parameters Stable Across Markets?
Our second test investigates whether between-market variation in the signs and magnitudes of
estimated mistakes can be explained by between-market variation in the factors that AG hypothÌ‚ ğ‘¢ denote a normalized vector of estimates for the ğ›½ paesize to be the sources of mistakes. Let Î’
rameters, where each element of the vector is divided by the estimated marginal utility of inÌ‚1,ğ‘¢ = ğ›½Ì‚1,ğ‘¢ â„ğ›¼Ì‚ğ‘¢ . The purpose of this normalization is to enable comparison across
come; e.g. Î’
markets. If observed violations are due to choice complexity and consumersâ€™ lack of cognitive
ability as AG hypothesize (p.1183-1184, 1209), and we estimate the model in two separate markets, ğ‘¢ and ğ‘£, in which consumers with the same cognitive abilities face different PDP menus
that are equally complex, then a well-specified model will yield two separate consistent estimates
for the same normalized parameter vector:
(8)

Ì‚ğ‘¢ = Î’
Ì‚ ğ‘£ âˆ€ ğ‘¢, ğ‘£ âˆ¶ ğ‘ğ‘¢ = ğ‘ğ‘£ and ğ‘§ğ‘¢ = ğ‘§ğ‘£ .
Î’

This restriction follows directly from (6). Similarly, under AGâ€™s hypothesis, we would expect the
magnitudes of violations to be smaller in regions where people have greater cognitive ability and
choose from simpler menus. To test these hypotheses we exploit the way CMS divides the nation

38

The results in the figure can be combined to evaluate the implied WTP for substitution of any placebo attributes, e.g. the results imply a WTP
of $114 for replacing two replacing two kâ€™s with two l's and a WTP of $98 for replacing two o's with 2 d's.
39
Abaluck and Gruber provided us with results for a slightly different approach to the placebo test, which for the sake of transparency we report
in Table A10. In addition to yielding similarly large implied WTP for placebo attributes, their analysis yields implied WTP for financial attributes
that differ widely from their original estimates and from our estimates.
40
The relatively larger WTP for full gap coverage could mean that consumers find this plan feature inherently attractive, or it could mean that full
gap coverage is more highly correlated with omitted variables, including observed but misspecified attributes, than our placebos. Some of the
possible omitted variables include higher moments of the cost distribution as well as aspects of risk protection not captured by the AG variance
measure. As one example, having gap coverage helps to smooth expenses across months, which may be important for retired people living on
fixed monthly incomes.

24

into regions with distinct PDP menus. We estimate the model separately for 32 of these regions
for 2006, excluding Alaska and Hawaii due to small samples. Holding cognitive ability and
menu complexity fixed, instability of the coefficients could indicate that the model is misspecified in ways that vary from market to market (ğœ‰ğ‘¢ â‰  ğœ‰ğ‘£ â‰  0) such as latent heterogeneity in preferences and unobserved PDP quality.41
In every region, our estimates violate at least two of AGâ€™s three parametric restrictions, but
the violations have inconsistent signs and magnitudes. Our data include between 1,462 and
42,441 people per region, so most of our estimates are statistically precise. Yet the estimated parameters are highly unstable. The ratio of the premium coefficient to the OOP coefficient provides a leading example. Figure 4 maps this ratio for each region. Focusing on the 24 markets in
which the estimated marginal utility of income is positive and statistically different from zero,
the premium-to-OOP ratio ranges from 1.1 in region 25 (IA, MN, MT, NE, ND, SD, WY) to
12.3 in region 2 (MA, CT, RI and VT). Taken literally, these results imply that the average consumer in region 25 would pay about $1 in higher OOP costs to reduce their plan premium by $1,
whereas the average consumer in region 2 would pay about $12 in OOP costs to reduce their
premium by $1.42

FIGURE 4â€”RATIO OF PREMIUM-TO-OOP COEFFICIENTS IN 2006, BY CMS REGION
Note: The figure reports the premium-to-OOP coefficient ratio obtained by estimating region-specific models equivalent to the national model in
column 3 of Table 4. In regions with light-shaded numbers, we fail to reject the null hypothesis that the marginal utility of income is negative at
the 5% level. Asterisks indicate that the premium-to-OOP ratio is statistically indistinguishable from 1 at the 5% level.

This can also be seen from the axioms underlying the proof of McFaddenâ€™s lemma 6 (McFadden 1974).
Figure A3 shows that the range across regions widens substantially if we replace our brand name dummies with the contract ID proxy for brand
used by AG. In that case, the premium-to-OOP ratio ranges from 1.2 in region 25 to 76.1 in region 4 (NJ).
41
42

25

All of the other parameter ratios are similarly unstable, as are the corresponding welfare losses. Most of the ratios span orders of magnitude and many include sign changes. The top part of
Table 5 illustrates this instability by comparing results from our national model to results for the
five largest CMS regions, which collectively represent 36% of the national sample. For example,
under the interpretation that AG give to their national results the ratios imply that people in regions 11 and 25 mistakenly prefer plans with more cost sharing whereas people in regions 4, 17,
and 22 mistakenly prefer plans with less cost sharing. Likewise, people in regions 4, 11, and 22
appear to be mistakenly attracted by generic gap coverage whereas people in regions 17 and 25
appeared to be mistakenly repelled by generic gap coverage.43 The bottom part of Table 5 reports
proxy measures for PDP menu complexity and the average consumerâ€™s cognitive ability. These
measures do not appear to explain the variation in parameter ratios and welfare measures across
the five regions.
Parameter ratios and welfare measures are similarly unstable across the other 27 CMS regions
as evident from the complete region-by-region results and summary statistics in Tables A13 and
A14. To summarize these results, we use the 24 regions with statistically significant positive estimates for the marginal utility of income to estimate a meta-regression of the conditional relationship between the premium-to-OOP ratio and proxy measures for menu complexity and cognitive ability,
(9)

ğ›¼Ì‚ğ‘¢ â„ğ›½Ì‚ğ‘‚ğ‘‚ğ‘ƒ,ğ‘¢ = ğœ‘ + ğ›¿ ğ‘§ğ‘¢ + ğœ”ğ‘ğ‘¢ + ğœ“,

where the dependent variable is the premium-to-OOP ratio for region u, the ğ‘§ğ‘¢ vector includes
the number of plans, the number of brands, the number of plans with gap coverage and the number of plans with zero deductible, and ğ‘ğ‘¢ includes the mean consumerâ€™s age and the percent of
consumers with dementia (including Alzheimerâ€™s disease). Our results fail to reject the joint hypothesis that ğ›¿ = ğœ” = 0 at the 10% level.44 We obtain similarly insignificant results when we repeat the regression using AGâ€™s welfare measure as the dependent variable, regardless of whether
We also observe similar instability in model parameters and welfare measures in Table 5 when use AGâ€™s proxy measures for brand dummies
and when we limit the sample to white females under the age of 80 who have not been diagnosed with Alzheimerâ€™s disease, dementia, or depression. Appendix Tables A11 and A12 report these results.
44
Measurement error introduced by using econometric estimates as the dependent variable in (9) may bias the standard errors downward, reinforcing our finding of statistical insignificance. As a robustness check on this finding, we repeat estimation of AGâ€™s model in (4) after adding
terms that interact ğ‘§ğ‘–ğ‘¢ and ğ‘ğ‘–ğ‘¢ with expected OOP expenditures (ğœ‡ğ‘–ğ‘— ), and then use the resulting estimates to predict the premium-to-oop ratio for
each region. These predictions are reported in the last row of tables A13 and A14. Consistent with our findings from the meta-regression, there is
little variation in the predicted ratios relative to what we observe in the region-specific estimates. Results from the model with interactions are reported in Table A16.
43

26

we allow ğœ€ğ‘–ğ‘— to enter utility. Results from the meta-regressions are reported in Table A15.
TABLE 5â€”SPATIAL VARIATION IN PARAMETER RATIOS, PDP MENUS, AND CONSUMERS, 2006
United
States

region region region region region
25
17
11
22
4

Estimated parameter ratios
premium / OOP

3.7
(0.0)

1.1
(0.0)

7.0
(0.2)

3.3
(0.2)

1.9
(0.1)

3.1
(1.1)

variance / premium

0.0
(0.0)

0.0
(0.0)

0.0
(0.0)

0.0
(0.0)

-0.8
(0.2)

0.6
(0.5)

deductible / premium

-0.1
(0.0)

-3.6
(0.2)

0.0
(0.0)

0.1
(0.0)

-0.5
(0.1)

-7.5
(2.9)

full gap / premium

-2.9
(0.0)

-2.9
(0.1)

-3.5
(0.1)

-3.3
(0.1)

0.6
(0.5)

0.5
(1.9)

generic gap / premium

-0.9
(0.0)

0.8
(0.6)

1.6
(0.1)

-0.1
(0.1)

-2.8
(0.3)

-8.8
(2.9)

cost share / premium

-1.7
(0.1)

-3.2
(0.9)

3.8
(0.2)

-10.9
(0.6)

5.0
(0.6)

48.1
(18.0)

top 100 / premium

-0.4
(0.0)

-0.4
(0.0)

-0.4
(0.0)

-0.5
(0.0)

-0.7
(0.0)

-0.5
(0.2)

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

39

92

18

38

62

110

7

24

9

9

3

68

43

41

42

43

47

44

19

23

18

20

22

20

7

7

6

8

6

6

26

23

25

25

27

25

PDP Menu
# plans
# brands
# plans w/ gap coverage
# plans w/ no deductible

Consumers
mean age
75
% with dementia
7.4
% off cost-var frontier
75
% off cost-var-brand frontier
26
521
mean potential savings
464,543
number

76

78

76

76

78

6.2

8.2

7.8

8.6

9.4

74

79

76

72

82

34
621

15
469

15
543

18
517

8
606

46,997 37,939 30,138 29,387 24,162
Note: The top portion of the table reports ratios of parameter estimates from our baseline model (Table 4 column 3) for selected CMS regions
with standard errors in parentheses. Region 25 includes Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Wyoming. Region 17
is Illinois; Region 11 is Florida; Region 22 is Texas; and Region 4 is New Jersey. Mean potential savings is the amount of money the average
consumer would have saved by switching to their lowest cost alternative.

In summary, the parameters of AGâ€™s behavioral model vary greatly across CMS regions and
these fluctuations produce order-of-magnitude differences in AGâ€™s measure of lost consumer
welfare. These differences are not explained by regional variation in PDP menu complexity and
proxy measures for the average consumerâ€™s cognitive ability. For this evidence to be interpreted

27

as supporting AGâ€™s hypotheses about consumer mistakes, the average consumers in different
CMS regions would have to be reacting to similarity complex PDP menus by making mistakes
that vary greatly in their severity (e.g. the magnitude of the premium-to-OOP ratio) and by making contradictory types of mistakes (e.g. changing signs of coefficients on financial attributes).
While enrollees may differ in the extent to which they make fully informed decisions, we would
expect this heterogeneity to be driven primarily by variation across consumers within CMS regions. Hence, we interpret the unexplained between-region variation in the parameters of AGâ€™s
behavioral model as evidence of potential model misspecification.
C. Test 3: Does Allowing for Mistakes Improve our Ability to Predict Choices?
Our last test builds on best practices in validation techniques to judge the usefulness of structural models for informing policy (e.g. McFadden et al. 1977, Keane and Wolpin 2007). In his
summary of the literature, Keane (2010) recommends evaluating the relative performances of
competing models of utility maximization based on two criteria: (i) their ability to reproduce important features of the data on which they were estimated; and (ii) their ability to make accurate
out-of-sample predictions for how agents will behave in different choice environments. We apply this logic in a new way and test whether allowing for specific mistakes improves a structural
modelâ€™s ability to predict peopleâ€™s choices. Specifically, we compare the accuracy of predictions
made by AGâ€™s DU model that allows for consumer mistakes (equation 4) with AGâ€™s less flexible
but otherwise identical expected utility maximization (EUM) model that maintains the assumption that consumers do not make any of the three explicit mistakes (equation 5). The two competing models correspond to columns 3 and 4 of Table 4, respectively. This comparison is relevant
for policy because AGâ€™s EUM model assumes no welfare loss from the three mistakes, i.e.
DU â‰¡ HU (setting aside AGâ€™s interpretation of the error terms) whereas AGâ€™s DU model allows
DU â‰  HU).
Because AGâ€™s DU model is more flexible it yields a better fit to the data on which it was estimated in the sense that it has a higher pseudo R-squared. The estimated coefficients also allow
us to reject the nested EUM model at the 1% level of statistical significance based on a Wald
test. Yet this rejection could be driven by model misspecification, such as correlation between
the financial plan characteristics and omitted measures of PDP cost, risk protection, and quality.
In this case AGâ€™s simpler EUM model could yield more accurate estimates for peopleâ€™s PDP

28

choice process and, therefore, more accurate predictions for how people would react to different
PDP choice environments. This is the reason for comparing the two models based on the accuracy of their out-of-sample predictions in a choice environment that differs from the in-sample environment. As Keane and Wolpin (2007) explain, in the absence of a controlled or natural experiment an effective approach to assessing the out-of-sample predictive power of competing
structural models is to use nonrandom holdout samples. The ideal holdout sample is nonrandom
in the sense that it should describe a market in which consumers choose among products with
combinations of attributes that differ from those of the products found in the market used to estimate the model. The model that better predicts how consumers behave under choice environments that differ from the environment under which the model was estimated would also be expected to yield more accurate estimates for consumer preferences and, therefore, to make better
predictions for the welfare effects of policies that alter the choice environment along similar dimensions.45
Our validation test is based on ğ‘ ğ‘¢ , a policy-relevant statistic describing market u that can be
observed in the data as well as predicted as a function of model parameters. The better performing model is the one that yields a lower value for
(8)

|ğ‘ Ì‚ğ‘¢ (ğ›¼Ì‚, ğ›½Ì‚ , ğ›¾Ì‚) âˆ’ ğ‘ ğ‘¢ |,

where ğ‘ Ì‚ğ‘¢ (ğ›¼Ì‚, ğ›½Ì‚ , ğ›¾Ì‚) is a prediction for ğ‘ ğ‘¢ based on the AGâ€™s DU or AGâ€™s EUM model. Following
standard practice, we call the predictions â€œin-sampleâ€ if they are based on estimates for ğ›¼, ğ›½, and
ğ›¾ from market u and â€œout-of-sampleâ€ if they are based on estimates from a different market (i.e.
a different CMS region). This is a high-power test in the sense that it is stacked against the less
flexible EUM model. Comparing the two models in Table 4 illustrates that AGâ€™s benchmark
EUM model constrains seven parameters of AGâ€™s DU model (the parameters of the mean and
variance of OOP cost and the five financial attributes). The additional flexibility of AGâ€™s DU
model increases its potential to reflect behaviors present in the data.
We use each model to predict seven outcomes broadly relevant to consumers and policymakers. The first is the share of consumers with some form of coverage in the gap. This clearly matters to policymakers given the scheduled transition to mandatory gap coverage in 2015. The secThis validation test differs from our regional comparison of AGâ€™s DU parameters in Table 5 in two ways. First, it is unclear a priori how differences in DU parameters across two regions will affect the accuracy of predictions for policy relevant statistics that are highly nonlinear functions
of those DU parameters. Second, the objective here is to compare AGâ€™s DU and EUM models, conditional on the fact that both use estimates
from one region to predict outcomes for other regions.
45

29

ond is the share of consumers choosing plans that are dominated in the sense that they lie off the
frontier in cost-variance-brand space. These consumers could have saved money by choosing a
lower-variance plan offered by their chosen brand. Both consumers and policymakers are likely
interested in reducing within-brand overspending. Third, we predict the share of consumers who
choose the lowest cost plan within their chosen brand, conditional on their chosen brand offering
multiple plans. This provides another proxy measure of ex post decision making quality. The
next two statistics describe the median consumerâ€™s expenditures. We predict total expenditures
(premium + OOP) as well as within-brand overspending on dominated plans. The last two statistics are the Herfindahl-Hirschman Index (HHI) and the market share of the most popular brand,
commonly used by regulators as measures of the degree of market competition.
To implement the validation test we select a single region as the estimation sample and use
the resulting parameters to predict choices in every other region. To be comprehensive we repeat
this procedure 32 times, iteratively using each region as the estimation sample, and then analyze
the combined results from the 32 in-sample predictions and all 992 possible out-of-sample predictions. To calculate an overall measure of model performance, the in-sample absolute prediction errors are weighted by the share of the CMS sample in each estimation region and the outof-sample predictions are weighted by the share in the holdout regions.46 The top half of Table 6
shows the results from models that rely on the CMS star ratings to proxy for plan quality, while
the lower half is from models that use the brand indicators.47
The first column in Table 6 reports the national values in the data while the next two columns
show the in-sample fit of AGâ€™s DU and EUM models in terms of mean absolute deviation. The
DU model is constrained to reproduce the in-sample share of consumers with gap coverage, and
when brand indicators are used to proxy for quality both the DU and EUM models are constrained to match the two market concentration measures. Among the remaining statistics, the
DU model usually does better as expected due to its greater flexibility.

46

In their comments on an earlier draft of this article, Abaluck and Gruber suggested using 31 regions as the estimation sample to predict choices
in the single remaining holdout region, and then repeating this exercise for each of the 32 regions. This is not an ideal test of a modelâ€™s out-ofsample predictive power. In the PDP context it is very similar to an in-sample test in the sense that the set of plans in the 31 estimation regions often comes very close to spanning the set of plans in the hold out region. This reduces the power of the test to reject the more flexible AG model in
favor of the EUM hypothesis. Nevertheless, we implement this test and report results in Table A19. AGâ€™s EUM model does as well or better than
their DU model on 11 out of 14 measures.
47
Many brands are not present in any given region. In those cases we assign brand indicator coefficients via an auxiliary regression. Specifically,
we regress the in-sample brand indicators on their CMS star ratings and use the estimated coefficient to impute any out-of-sample brand indicators that are not present in the estimation sample.

30

TABLE 6â€” NONRANDOM HOLDOUT SAMPLE TESTS OF MODEL VALIDATION, 2006

data

In-sample fit

Out-of-sample fit

AG's DU AG's EUM

AG's DU AG's EUM

|model error |

|model error |

Using CMS Star Ratings for Quality
Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

13
20
52

0
3
6

6
4
6

7
7
8

6
6
6

1,255
0

13
65

37
53

76
64

65
50

25
37

9
9

14
17

9
11

13
16

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

Using Brand Indicators for Quality
Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

13
20
52

0
1
5

4
3
8

7
7
11

7
7
10

1,256
0

13
74

18
66

75
82

73
66

25
37

0
0

0
0

10
14

10
13

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

Note: | Model error | refers to the mean absolute deviation between the regional-level model predictions and data, weighted across regions by the
number of people in the sample in the region. The results are based on every possible pairwise combination of regions in 2006 except that they
exclude regions 33 and 34 (HI and AK) due to small samples, and the lower half also excludes region 26 (NM) because the generic gap indicator
is collinear with the brand indicators for that region. Thus the values in the top half are based on the results from all 992 of the possible regional
out-of-sample predictions while those in the lower half are based on 930 of them.

The last two columns of Table 6 summarize each modelâ€™s out-of-sample predictive power.
We expect both models to perform worse out of sample, but the DU model has a relatively larger
reduction in predictive power. Importantly, the EUM model yields predictions that are as close or
closer to the data for 12 of the 14 measures. The fact that AGâ€™s DU model does better at predicting the two measures of market concentration when star ratings are used to proxy for quality
could be because the additional seven parameters of the DU model give it greater flexibility to
capture latent features of PDP quality when brand indicators are omitted.
Because using brand indicators for quality requires imputing coefficients for brands that are
offered in the prediction region but not the estimation region, we perform a robustness check in
which we limit the validation exercise to region pairs for which one regionâ€™s brands is nested in
31

the otherâ€™s. This allows inclusion of brand indicators without imputation. The results of this exercise, reported in Table A17, affirm the national results in the lower half of Table 6, as do results from repeating the exercise in Table 6 using the root mean square error as the test statistic
in lieu of the mean absolute deviation (Table A18). Altogether, these results demonstrate that
AGâ€™s benchmark model without welfare reducing mistakes leads to predictions for policyrelevant statistics that typically match the data on peopleâ€™s PDP choices about as well, and often
better, than predictions from AGâ€™s model with optimization mistakes.
VI. Conclusion
Neoclassical and psychological models of consumer behavior often make divergent predictions for the welfare effects of paternalistic policies. As Bernheim and Rangel (2009) observed,
the lack of methodological consensus within economics results in analysts selecting models for
policy evaluation based on ad hoc criteria that are inevitably controversial. Within this conflicted
environment, researchersâ€™ assumptions about what they know about other peoplesâ€™ preferences,
constraints, and information have wide scope to influence the researchersâ€™ interpretations of results and their conclusions about the effects of various policies. One of our objectives for this article was to overcome this impasse by developing a broadly applicable three-step approach to
evaluating the role and validity of modeling assumptions underlying conclusions about the quality of consumer decision making.
The first step is to integrate parametric and nonparametric tests of utility maximization by using internally consistent assumptions about which product attributes affect utility. The nonparametric results will reveal whether inferences based on the analystâ€™s chosen parametric model are
robust to alternative specifications for utility. If the results are not robust, then the next step is to
calculate nonparametric measures of the sufficient willingness to pay for product attributes.
These measures help to clarify the tradeoffs implied by the set of utility functions that are maximized by consumersâ€™ choices. Finally, we propose designing tests to disentangle consumer mistakes from the researcherâ€™s misspecification of their utility functions. Of particular value are
head-to-head validation tests of modelsâ€™ out-of-sample predictive power that build on McFadden
(1977) and Keane and Wolpin (2007). That is, a key step in establishing that consumers are making specific welfare-reducing mistakes is to first show that incorporating such mistakes into a
model improves its predictions for how consumers react to changes in the choice environment.

32

In the context of Medicare Part D, our nonparametric tests revealed that Abaluck and Gruberâ€™s
(2011) [AG] parametric evidence that enrollees made large welfare reducing optimization mistakes in 2006 is not robust to alternative specifications for utility. We showed that these alternative specifications imply that the median consumer must have been willing to pay at least $80
(6% of total out of pocket expenditures) in 2006 for all between-brand differences in plan quality. We also found that a simpler version of AGâ€™s model that maintains the hypothesis of expected utility maximization makes out-of-sample predictions that are typically as good, and often
better, than their model with psychological biases. These empirical results cast doubt on the notion that the three mistakes in AGâ€™s model have an important influence on how people choose insurance plans. They also cast doubt on the notion that people would benefit from policies that
would restrict their ability to choose insurance plans for themselves. That said, our results do not
imply that everyone always makes fully informed enrollment decisions or that nobody would
benefit from paternalistic policies. Rather, our results imply that evaluating the distributional
welfare implications of paternalistic reforms to health insurance markets requires us to first develop a better understanding of how heterogeneous consumers obtain and process information
about differentiated health insurance products with uncertain payoffs.

REFERENCES
Abaluck, Jason T., and Jonathan Gruber. 2011. â€œChoice Inconsistencies among the Elderly: Evidence from Plan Choice in the Medicare Part D Program.â€ American Economic Review
101(4): 1180-1210.
Abaluck, Jason T., and Jonathan Gruber. 2013. â€œEvolving Choice Inconsistencies in Choice of
Prescription Drug Insurance.â€ NBER Working Paper 19163.
Agarwal, Sumit and Bhashkar Mazumder. 2013. â€œCognitive Abilities and Household Financial
Decision Makingâ€. American Economic Journal: Applied Economics 5(1): 193-207.
Bernheim, B. Douglas and Antonio Rangel. 2009. â€œBeyond Revealed Preference: ChoiceTheoretic Foundations for Behavioral Welfare Economics-super.â€ Quarterly Journal of Economics, 124(1): 51-104.
Camerer, Colin, Samuel Issacharoff, George Lowenstein, Ted Oâ€™Donoghue, and Matthew Rabin.
2003. â€œRegulation for Conservatives: Behavioral Economics and the Case for â€œAsymmetric
Paternalismâ€. University of Pennsylvania Law Review 151(3): 1211-1254.

33

Cardon, James H., and Igal Hendel. 2001. â€œAsymmetric information in health insurance: evidence from the National Medical Expenditure Survey.â€ RAND Journal of Economics 32(3):
408-427.
Einav, Liran, Amy Finkelstein, Stephen P. Ryan, Paul Schrimpf, and Mark R. Cullen. 2013. â€œSelection on Moral Hazard in Health Insurance.â€ American Economic Review 103(1):178-219.
Gabaix, Xavier, and David Laibson. 2006. â€œShrouded Attributes, Consumer Myopia, and Information Suppression in Competitive Markets.â€ Quarterly Journal of Economics 121 (2): 505â€“
40.
Goldman, Dana P. and Tomas Philipson. 2007. â€œIntegrated Insurance Design in the Presence of
Multiple Medical Technologies.â€ American Economic Review AEA Papers and Proceedings,
97(2): 427-432.
Handel, Benjamin R. 2013. "Adverse selection and inertia in health insurance markets: When
nudging hurts." American Economic Review 103(7): 2643-2682.
Kahneman, Daniel, Peter P. Wakker, and Rakesh Sarin. 1997. â€œBack to Bentham? Explorations
of Experienced Utility.â€ Quarterly Journal of Economics 112(2): 375-405.
Kariv, Shachar and Dan Silverman. 2013. â€œAn Old Measure of Decision-making Quality Sheds
New Light on Paternalism.â€ Journal of Institutional and Theoretical Economics 169(1): 2944.
Keane, Michael P. 2010. â€œStructural vs. Atheoretic Approaches to Econometrics.â€ Journal of
Econometrics 156 (1): 3-20.
Keane, Michael P. and Kenneth I. Wolpin. 2007. â€œExploring the Usefulness of a Non-random
Holdout Sample for Model Validation: Welfare Effects on Female Behavior.â€ International
Economic Review 48(4): 1351-1378.
Ketcham, Jonathan D., Claudio Lucarelli, and Christopher Powers. 2014. â€œPaying Attention or
Paying Too Much in Medicare Part D.â€ American Economic Review, 105(1): 204-233.
Lancaster, Kelvin J. 1966. "A New Approach to Consumer Theory." Journal of Political Economy 74(2): 132-57.
Leamer, Edward E. 1983. "Let's Take the Con Out of Econometrics." American Economic Review 73(1): 31-43.
Madrian, Brigitte, and Dennis F Shea. 2001. â€œThe Power of Suggestion: Inertia in 401(k) Participation and Savings Behavior.â€ The Quarterly Journal of Economics 116(4): 1149-87.

34

McFadden, Daniel. 1974. "Conditional Logit Analysis of Qualitative Choice Behavior," in Frontiers in Econometrics. Paul Zarembka ed. New York: Academic Press.
McFadden, Daniel, Antti P. Talvitie, and associates. 1977. Urban Travel Demand Forecasting
Project Phase 1 Final Report Series, Vol. 5. University of California Institute of Transportation Studies Special Report 77-9.
McGuire, Thomas T. 2012. â€œDemand for Health Insurance.â€ In Handbook of Health Economics
Volume 2, Mark V. Pauly, Thomas G. McGuire and Pedro P. Barros, eds. New York: NorthHolland.
MedPAC, 2006. â€œChapter 8. How beneficiaries learned about the drug benefit and made plan
choices.â€ In Report to the Congress, Increasing the Value of Medicare.
Miravete, Eugenio J. 2013. â€œCompetition and the Use of Foggy Pricing.â€ American Economic
Journal: Microeconomics 5(1): 194-216.
Spiegler, Ran. 2011. Bounded Rationality and Industrial Organization. New York: Oxford University Press.
Stigler, George J. 1966. The Theory of Price, 3rd edition. New York: MacMillan Company.
Varian, Hal R. 1983. â€œNonparametric Tests of Consumer Behavior.â€ Review of Economic Studies
50(1): 99-110.
Woodward, Susan E and Robert E Hall. 2012. â€œDiagnosing Consumer Confusion and SubOptimal Shopping Effort: Theory and Mortgage-Market Evidence.â€ American Economic Review 102(7): 3249-3276.
Zeckhauser, Richard. 1970. â€œMedical Insurance: A Case Study of the Tradeoff between Risk
Spreading and Appropriate Incentives.â€ Journal of Economic Theory 2: 10-26.

35

SUPPLEMENTAL APPENDIX FOR ONLINE PUBLICATION
I. DERIVING ABALUCK AND GRUBERâ€™S WELFARE MEASURES
AG begin by assuming that consumersâ€™ decisions are guided by a logit model that is linear and
additively separable in PDP characteristics, as shown in (4) and repeated here for convenience.
(A1)

ğ‘¢Ì‚ğ‘–ğ‘— = ğœ”
Ì‚ğ‘–ğ‘— + ğœ€Ì‚ğ‘–ğ‘— = ğ‘ğ‘— ğ›¼Ì‚ + ğœ‡ğ‘–ğ‘— ğ›½Ì‚1 + ğœğ‘–ğ‘—2 ğ›½Ì‚2 + ğ‘ğ‘— ğ›½Ì‚3 + ğ‘ğ‘— ğ›¾Ì‚ + ğœ€Ì‚ğ‘–ğ‘— .

In contrast, the actual utility a consumer experiences from her selected PDP is instead defined by
the following hedonic utility function that satisfies AGâ€™s three normative restrictions,
(A2)

ğ‘¢ğ‘–ğ‘— = ğœ”ğ‘–ğ‘— + ğœ€ğ‘–ğ‘— = ğ‘ğ‘— ğ›¼Ì‚ + ğœ‡ğ‘–ğ‘— ğ›¼Ì‚ + ğœğ‘–ğ‘—2 ğ›½Ìƒ2 + ğ‘ğ‘— ğ›¾Ì‚ + ğœ€ğ‘–ğ‘— , where ğ›½Ìƒ2 < 0.

Because AG assume the marginal utility of income is a constant revealed by ğ›¼Ì‚, a consumerâ€™s expected welfare from choosing plan j can be expressed as
(A3)

1

ğ¸[ğ¶ğ‘†ğ‘– ] = ğ›¼Ì‚ ğ¸[ğ‘¢ğ‘–ğ‘— |ğ‘¢Ì‚ğ‘–ğ‘— > ğ‘¢Ì‚ğ‘–ğ‘˜ âˆ€ ğ‘˜].

PDP choice and welfare are both deterministic from the consumerâ€™s perspective. The expectation
in (A3) simply reflects the analystâ€™s inability to observe ğœ€Ì‚ğ‘–ğ‘— .
AG aim to calculate the partial equilibrium welfare gain from a hypothetical intervention
â€œthat would make individuals fully informed and fully rationalâ€ (p 1208). In other words, they
want to calculate the welfare gain from a policy that would induce the consumer to choose the
PDP that maximizes AGâ€™s normative utility function (A2) instead of (A1). Assuming the policy
has no effect on the marginal utility of income, the welfare gain can be expressed in general
terms as
(A4)

1

Î”ğ¸[ğ¶ğ‘†ğ‘– ] = ğ›¼Ì‚ ğ¸[maxğ‘˜ {ğ‘¢ğ‘–ğ‘˜ } âˆ’ (ğ‘¢ğ‘–ğ‘— |ğ‘¢Ì‚ğ‘–ğ‘— > ğ‘¢Ì‚ğ‘–ğ‘˜ âˆ€ ğ‘˜)].

The analytical formula depends on the interpretation of the residual utility terms, ğœ€Ì‚ğ‘–ğ‘— and ğœ€ğ‘–ğ‘— .
In appendix D of the NBER (2009) version of their paper, AG outline two different approaches to interpreting residual utility. The more conventional approach, laid out in earlier papers such as Leggett (2002), is to interpret ğœ€Ì‚ğ‘–ğ‘— as the idiosyncratic utility from PDP characteristics that consumers observe but the analyst does not. Examples include proximity to in-network
pharmacies, availability of mail-order pharmacies, individual-specific experience with the insurA1

ers, coordination with spouses, disutility from prior authorization requirements, uncertainty
about whether other plans will approve prior authorization requests, and so on. In this case the
policy intervention has no effect on the utility residual because the same unobserved PDP attributes enter hedonic utility.48 Thus ğœ€ğ‘–ğ‘— = ğœ€Ì‚ğ‘–ğ‘— .
In contrast, the approach that Abaluck and Gruber (2011, 2013) use for their published empirical analyses is to assume that the policy intervention also eliminates the utility residual:
ğœ€ğ‘–ğ‘— = 0. That is, ğœ€ğ‘–ğ‘— itself is treated as an optimization mistake in addition to violations in the
three parametric restrictions that they explicitly mention as reducing welfare (p.1208). This approach embeds at least three important assumptions. First, it assumes there are no omitted variables. The analyst must have data on every PDP attribute that affects consumersâ€™ hedonic utility.
Second, it assumes (A1) and (A2) are correctly specified. The analyst must know the true parametric forms of decision utility and hedonic utility. Third, it assumes the policy intervention has
no direct effect on utility. For example, the two policies suggested in AG may affect welfare due
to distaste for being nudged or distaste for sacrificing control over plan choices to a surrogate decider. Together, these three assumptions are required for AG to treat ğœ€Ì‚ğ‘–ğ‘— as an idiosyncratic optimization mistake that is eliminated by their hypothetical policy.
In the remainder of this section we derive analytical formulas for consumer welfare under
each of the two approaches to interpreting residual utility. Whereas Abaluck and Gruber (2009)
derive measures of baseline consumer surplus prior to any policy intervention, we derive the key
statistic used in their welfare calculations (and ours)â€”the change in consumer welfare caused by
the hypothetical policy â€œthat would make individuals fully informed and fully rationalâ€.
Case 1. Residual Utility is an Optimization Mistake: ğœºğ’Šğ’‹ â‰¡ ğŸ âˆ€ğ’Šğ’‹
In this case the analyst can calculate baseline consumer surplus for each individual by using the
marginal utility of income to translate utils into dollars:
(A5)

ğ¸[ğ¶ğ‘†ğ‘– ] = ğ¶ğ‘†ğ‘– =

ğœ”ğ‘–ğ‘—
Ì‚
ğ›¼

.

After consumers are made to choose the plans that maximize AGâ€™s normative utility function the
post-policy consumer surplus becomes
As we point out in section IV, ğœ€Ì‚ğ‘–ğ‘— may also reflect misspecification of the true parametric form of decision utility. In this case ğœ€ğ‘–ğ‘— may differ
from ğœ€Ì‚ğ‘–ğ‘— if the policy affects the marginal decision utility of one or more PDP attributes included in ğœ€Ì‚ğ‘–ğ‘— .
48

A2

(A6)

1

ğ¸[ğ¶ğ‘†ğ‘–âˆ— ] = ğ¶ğ‘†ğ‘–âˆ— = Ì‚ maxğ‘˜ {ğœ”ğ‘–ğ‘˜ }.
ğ›¼

Hence the change in welfare generated by the hypothetical policy is
(A7)

1

âˆ†ğ¸[ğ¶ğ‘†ğ‘– ] = ğ¶ğ‘†ğ‘–âˆ— âˆ’ ğ¶ğ‘†ğ‘– = ğ›¼Ì‚ [maxğ‘˜ {ğœ”ğ‘–ğ‘˜ } âˆ’ ğœ”ğ‘–ğ‘— ].

Since ğœ€ğ‘–ğ‘— â‰¡ 0 the analyst can calculate actual consumer surplus instead of expected consumer
surplus.
Case 2: Residual Utility Reflects Omitted Attributes ğœºÌ‚ğ’Šğ’‹ = ğœºğ’Šğ’‹ âˆ€ğ’Šğ’‹
In this case the analyst must integrate over the assumed Type I EV distribution for ğœ€Ì‚ğ‘–ğ‘— to calculate expected consumer surplus prior to the policy. The resulting expression in (A8) depends on
the standard log sum rule as well as the difference between decision utility and hedonic utility
weighted by the probability of selecting each PDP (e.g. Small and Rosen 1981, Leggett 2002,
Abaluck and Gruber 2009).
(A8)

1

ğ¸[ğ¶ğ‘†ğ‘– ] = ğ›¼Ì‚ [ğ‘™ğ‘› âˆ‘ğ‘˜ ğ‘’ ğœ”Ì‚ğ‘–ğ‘˜ + âˆ‘ğ‘—(ğœ”ğ‘–ğ‘— âˆ’ ğœ”
Ì‚ğ‘–ğ‘— ) âˆ‘

Ì‚
ğœ”
ğ‘’ ğ‘–ğ‘—

Ì‚
ğœ”
ğ‘˜ ğ‘’ ğ‘–ğ‘˜

] + ğ¶Ì‚ .

In the equation, ğ¶Ì‚ represents the constant of integration divided by ğ›¼Ì‚. It arises from the assumed
Type I EV distribution for ğœ€Ì‚ğ‘–ğ‘— and the fact that the level of utility is unknown.
The policy intervention eliminates the wedge between decision utility and hedonic utility,
simplifying calculation of post-policy consumer surplus:
(A9)

1

ğœŒ

ğ¸[ğ¶ğ‘†ğ‘–âˆ— ] = ğ›¼Ì‚ [ğ‘™ğ‘› âˆ‘ğ‘˜ ğ‘’ ğœ”ğ‘–ğ‘˜ ] + ğ¶, where = ğ¶Ì‚ + ğ›¼Ì‚ .

If the policy intervention has a direct effect on utility, defined here by ğœŒ, then the post-policy
constant of integration, ğ¶, differs from the pre-policy constant of integration.49 On the other
hand, if we follow AG in assuming that the policy has no direct effect on utility then ğœŒ = 0 and
ğ¶ = ğ¶Ì‚ . In this case, the change in expected consumer surplus is
(A10)

49

1
Ì‚
ğ›¼

1

âˆ‘ ğ‘’ ğœ”ğ‘–ğ‘˜

âˆ†ğ¸[ğ¶ğ‘†ğ‘– ] = ğ¸[ğ¶ğ‘†ğ‘–âˆ— ] âˆ’ ğ¸[ğ¶ğ‘†ğ‘– ] = ğ›¼Ì‚ [ğ‘™ğ‘› âˆ‘ğ‘˜

ğ‘˜ğ‘’

Ì‚ğ‘–ğ‘— ) âˆ‘
Ì‚ ğ‘–ğ‘˜ âˆ’ âˆ‘ğ‘— (ğœ”ğ‘–ğ‘— âˆ’ ğœ”
ğœ”

Ì‚
ğœ”
ğ‘’ ğ‘–ğ‘—

Ì‚
ğœ”
ğ‘˜ ğ‘’ ğ‘–ğ‘˜

].

1

We assume that any direct effect of the policy on utility is additive and invariant to PDP choice so that ğ¸[ğ¶ğ‘†ğ‘–âˆ— ] = Ì‚ maxğ‘˜ {ğœ”ğ‘–ğ‘˜ + ğœ€ğ‘–ğ‘— } =
ğ›¼
1
1
1
1
1
[ğ‘™ğ‘› âˆ‘ğ‘˜ ğ‘’ ğœ”ğ‘–ğ‘˜+ğœŒ ] + ğ¶Ì‚ = [ğ‘™ğ‘› âˆ‘ğ‘˜ ğ‘’ ğœŒ ğ‘’ ğœ”ğ‘–ğ‘˜ ] + ğ¶Ì‚ = [ğ‘™ğ‘›(ğ‘’ ğœŒ âˆ‘ğ‘˜ ğ‘’ ğœ”ğ‘–ğ‘˜ )] + ğ¶Ì‚ = [ğ‘™ğ‘›(ğ‘’ ğœŒ )] + [ğ‘™ğ‘› âˆ‘ğ‘˜ ğ‘’ ğœ”ğ‘–ğ‘˜ ] + ğ¶Ì‚ = [ğ‘™ğ‘› âˆ‘ğ‘˜ ğ‘’ ğœ”ğ‘–ğ‘˜ ] + ğ¶.
Ì‚
ğ›¼

Ì‚
ğ›¼

Ì‚
ğ›¼

Ì‚
ğ›¼

Ì‚
ğ›¼

A3

Equation (A10) isolates the combined welfare effect of imposing the three normative restrictions on utility that AG emphasize. In contrast, the 27% welfare gain that AG report in their
conclusion is based on the calculation in (A7) that embeds their normative restrictions along with
the added assumption that residual utility consists entirely of optimization mistakes. Therefore,
comparing empirical results for (A7) and (A10) will reveal the extent to which AGâ€™s reported
27% potential welfare gain is driven by the particular optimization mistakes they emphasize relative to their novel interpretation of the Type I EV logit error term.
Leggett, Christopher G. 2002. â€œEnvironmental Valuation with Imperfect Informationâ€. Environmental
and Resource Economics. 23: 343-355.
Small, Kenneth A. and Harvey S. Rosen. 1981. â€œApplied Welfare Economics with Discrete Choice Models.â€ Econometrica. 49(1): 105-130.

A4

II. ADDITIONAL RESULTS

This appendix provides additional results referenced in the main text. Table A1 provides an
example of the difference between AGâ€™s definition for brand dummies that relies on CMS contract ID codes that are unobserved by consumers and our definition that relies on company and
plan names observed by consumers. We define AARP and UnitedHealth as two distinct brands,
whereas AG group one AARP plan and one UnitedHealth plan into one brand, and two AARP
plans and one UnitedHealth plan into a separate brand.
TABLE A1â€”EXAMPLE OF THE DIFFERENCE BETWEEN CONTRACT ID AND BRAND NAME DUMMY VARIABLES
Plan Name
AARP MedicareRx Plan
AARP MedicareRx Plan - Enhanced
AARP MedicareRx Plan - Saver
UnitedHealth Rx Basic
UnitedHealth Rx Extended

Brands #1 and #2 using:
contract ID
brand name
1
1
2
1
2
1
2
2
1
2

Note: Example is from the Region 2 (CT, MA, RI and VT) in 2007.

Figure A1 reports the gap premium and gap enrollment rates for various alternative samples.
Panel A shows that the divergence between AGâ€™s results and results from the CMS data widens
when part-year enrollees are included in the CMS sample as they likely were in AGâ€™s sample.
The remaining panels provide further evidence that people responded to how gap coverage mattered for themselves. Panel B depicts CMS region 25 which was the region with the largest number of (non-poor) PDP enrollees. It is comprised of Iowa, Minnesota, Montana, Nebraska, North
Dakota, South Dakota, and Wyoming. People in these states had exclusive access to a plan with
especially generous gap coverage, as seen from comparing the cost premia in panel B with that
in Figure 1B. They responded by enrolling at much higher ratesâ€”up to 75% at the 98th expenditure quantile. Thus, enrollment in gap plans varied dramatically across regions with the regional
rate of enrollment increasing in the generosity of coverage.

A5

A. 2006 including part-year enrollees

B. 2006, region 25

C. 2007

D. 2008

E. 2009

F. 2010

FIGURE A1: PERCENT CHOOSING GAP COVERAGE AND ADDED COST BY EXPENDITURE QUANTILE

Table A2 summarizes how the average consumerâ€™s chosen plan differs from other plans the
consumer could have chosen. Each cell reports the difference between an attribute of the consumerâ€™s chosen plan and the mean value of that same attribute calculated over all of the plans
that the consumer could have chosen but did not. For example, in 2006 the average consumer
paid $112 less in out of pocket costs for prescription drugs under her chosen plan then she would
have paid, on average, if she had enrolled in a different plan than was available to her.
A6

TABLE A2â€”DIFFERENCE BETWEEN THE CHOSEN PLAN AND THE MEAN ALTERNATIVE
sample size
premium (difference in $)
out of pocket costs (difference in $)
variance of OOP costs (difference in percentage points)
count of top 100 drugs covered (difference in number of drugs)
CMS quality index (difference in percentage points)

2006
464,543
-89
-112
-16
2
6

2007
566,962
-73
-109
27
1
5

2008
602,992
-65
-164
36
1
2

2009
614,714
-62
-140
-5
1
7

2010
629,225
-53
-187
-7
1
0

Note: Each row is calculated as the average over all people of the difference between the attribute of their chosen plan and the average of that
same attribute calculated over all others plans in the individualâ€™s choice set. The unit of analysis is the individual person.

Table A3 provides the share of people in 2006 and 2007 that could reduce their spending by
certain amounts by moving from their plan without gap coverage into the cheapest plan with gap
coverage, or by moving from their plan with gap coverage into the cheapest plan without gap
coverage.
TABLE A3â€”POTENTIAL SAVINGS FROM MOVING INTO OR OUT OF A GAP PLAN, 2006-2007

2006

2007

Percent who could save more than $X Into a gap Out of a
by moving
plan
gap plan
$100
9.9
4.2
$300
8.0
2.3
$500
4.2
0.1
$750
2.5
0.0
$1,000
1.4
0.0

Into a gap Out of a
plan
gap plan
6.6
8.6
3.7
1.3
2.2
0.2
1.2
0.1
0.6
0.0

Table A4 repeats the nonparametric analysis in Table 2 after replacing our brand dummies
(based on company name) with AGâ€™s brand dummies (based on contract IDs).
TABLE A4â€” NONPARAMETRIC TEST OF CHOICE INCONSISTENCY WITH BRAND DUMMY VARIABLES DEFINED USING
CONTRACT ID

(1)
(2)
(3)
(4)
(5)

Plan attributes affecting utility

Assumption on expected
drug expenditures in year t

E[cost]

year t drug consumption

E[cost], var(cost)

year t drug consumption

E[cost], var(cost), CMS quality

year t drug consumption

E[cost], var(cost), brand

year t drug consumption

E[cost], var(cost), brand

year t or t-1 drug consumption

% Consumers choosing frontier plans
2006

2007

2008

2009

2010

7
25
35
74

7
24
33
77
81

10
24
46
80
86

6
26
42
87
91

8
36
45
87
90

A7

cost

a
SWTP

b
c

var

FIGURE A2â€”ILLUSTRATION OF THE SUFFICIENT WILLINGNESS TO PAY FOR BRAND

Figure A2 illustrates how we calculate the sufficient willingness to pay (SWTP) for the bundle of unobserved PDP attributes that vary from brand to brand. To begin, consider a plan, a, that
lies on the efficiency frontier in cost-variance-brand space, where cost means the total cost (premiums plus ex post OOP drug costs) to the individual. Figure A2 is projected in cost-variance
space. The dots represent other available plans. Plans on the efficiency frontier in cost-variance
space have dark shading; plans off the frontier have light shading. The area inside the rectangle
defined by the dashed lines that intersect at point a defines the portion of the efficiency frontier
where other plans dominate a in cost-variance space. In the figure there are two such plans, b and
c. We define SWTP as the amount of income the consumer gives up by choosing to purchase
plan a instead of the most expensive plan on the portion of the cost-variance frontier that dominates plan a. Hence, ğ‘†ğ‘Šğ‘‡ğ‘ƒ = ğ‘ğ‘œğ‘ ğ‘¡ğ‘ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ .
SWTP can be interpreted as an arbitrarily close approximation to the willingness to pay for
latent attributes of the consumerâ€™s preferred brand for a consumer with preferences satisfying
basic axioms of consumer preference theory. To see why, suppose that plan a is sold by brand A
whereas plans b and c are sold by brand B, and the two brands differ in a vector of latent quality
A8

attributes, q. Consider a consumer who prefers plan b to plan c and is indifferent between plans b
and a such that
ğ‘ˆ(ğ‘¦ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ , ğ‘£ğ‘ğ‘Ÿğ‘ , ğ‘ğµ )
= ğ‘ˆ(ğ‘¦ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ , ğ‘£ğ‘ğ‘Ÿğ‘ , ğ‘ğ´ )

(A11)

= ğ‘ˆ(ğ‘¦ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ âˆ’ ğ‘†ğ‘Šğ‘‡ğ‘ƒ, ğ‘£ğ‘ğ‘Ÿğ‘ , ğ‘ğ´ ),
where the last line follows from the definition of SWTP. The consumerâ€™s exact willingness to pay
(WTP) to switch from ğ‘ğµ to ğ‘ğ´ , evaluated at the best available point on the efficiency frontier in
cost-variance space, is implicitly defined by the following equation
(A12)

ğ‘ˆ(ğ‘¦ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ , ğ‘£ğ‘ğ‘Ÿğ‘ , ğ‘ğµ ) = ğ‘ˆ(ğ‘¦ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ âˆ’ ğ‘Šğ‘‡ğ‘ƒ, ğ‘£ğ‘ğ‘Ÿğ‘ , ğ‘ğ´ ).

Combining (A11) and (A12) yields the following expression
(A13)

ğ‘ˆ(ğ‘¦ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ âˆ’ ğ‘†ğ‘Šğ‘‡ğ‘ƒ, ğ‘£ğ‘ğ‘Ÿğ‘ , ğ‘ğ´ ) = ğ‘ˆ(ğ‘¦ âˆ’ ğ‘ğ‘œğ‘ ğ‘¡ğ‘ âˆ’ ğ‘Šğ‘‡ğ‘ƒ, ğ‘£ğ‘ğ‘Ÿğ‘ , ğ‘ğ´ ).

Assuming the consumerâ€™s preferences satisfy global risk aversion and strong monotonicity it
must be the case that ğ‘Šğ‘‡ğ‘ƒ > ğ‘†ğ‘Šğ‘‡ğ‘ƒ. This follows from (A13) because quality is held constant
at ğ‘ğ´ . That is, in order to hold utility constant when the variance decreases from ğ‘£ğ‘ğ‘Ÿğ‘ to ğ‘£ğ‘ğ‘Ÿğ‘ ,
the risk averse consumerâ€™s income must be reduced. Thus, ğ‘Šğ‘‡ğ‘ƒ = ğ‘†ğ‘Šğ‘‡ğ‘ƒ + ğœ€, where ğœ€ is a positive constant that reflects the willingness to pay to reduce the variance from ğ‘£ğ‘ğ‘Ÿğ‘ to ğ‘£ğ‘ğ‘Ÿğ‘ at ğ‘ğ´ .
Finally, notice that ğœ€ can be made arbitrarily close to zero (e.g. one tenth of one cent) without violating completeness, transitivity, strong monotonicity or risk aversion. It follows that ğ‘†ğ‘Šğ‘‡ğ‘ƒ
provides an arbitrarily close approximation to the willingness to pay for latent attributes of the
consumerâ€™s preferred brand, conditional on cost and variance, that is sufficient to rationalize the
consumerâ€™s observed choice. Also notice that SWTP equals 0 for any plan on the efficiency frontier in cost-variance space, whereas no value for SWTP can rationalize the choice of a plan that
lies off the efficiency frontier in cost-variance-brand space.
This logic generalizes to any number of plans on the portion of the efficiency frontier that
dominates plan a in cost-variance space. Regardless of the thickness or sparseness of plans in attribute space, we can always set ğœ€ to be less than e, where e is an arbitrarily small positive constant. Likewise, this logic can be generalized to any assignment of plans to brands by restricting
the consumer to have identical tastes for the vector of latent attributes associated with brands B,
C, D, and so on.
A9

Table A5 reports results from our replication of the first three columns of Table 1 in AG. The
columns of the two tables are directly comparable, and both rely on AGâ€™s definition of the brand
dummy variables. Models with AGâ€™s brand-state dummies (AGâ€™s column (4)) do not converge.
TABLE A5â€” REPLICATION OF AG TABLE 1 USING CMS DATA
(1)

(2)

(3)

Premium (hundreds)

-0.352***
(0.00110)

-0.430***
(0.00143)

-0.559***
(0.00249)

OOP costs (hundreds)

-0.161***
(0.000478)

-0.102***
(0.000562)

-0.102***
(0.000578)

-0.000136***
(5.28e-05)

-0.000124**
(5.17e-05)

-4.86e-05
(6.54e-05)

Deductible (hundreds)

-0.101***
(0.00169)

-0.0201***
(0.00281)

full gap coverage

0.818***
(0.00887)

1.897***
(0.0146)

generic gap coverage

0.216***
(0.00685)

0.529***
(0.00907)

Cost sharing

-1.205***
(0.0156)

-0.313***
(0.0248)

Number of top 100
drugs on formulary

0.184***
(0.00107)

0.190***
(0.00153)

Variance (millions)

CMS quality index
Brand dummies
Number of consumers
Number of plans
Number of states
Number of brands
Pseudo R2

4.217***
(0.00996)

3.322***
(0.0112)

No

No

Yes

464,543

464,543

464,543

1,348
48
73
0.17

1,348
48
73
0.20

1,348
48
73
0.32

A10

Table A6 reports results from estimating the model in column (3) of Table 4 for each year
from 2006 through 2010.
TABLE A6â€” SENSITIVITY OF MAIN RESULTS FROM AGâ€™S FULL MODEL TO THE STUDY YEAR
2006

2007

2008

2009

2010

Premium (hundreds)

-0.402***
(0.00246)

-0.144***
(0.00180)

-0.355***
(0.00161)

-0.505***
(0.00183)

-0.565***
(0.00201)

OOP costs (hundreds)

-0.108***
(0.000573)

-0.108***
(0.000580)

-0.214***
(0.000836)

-0.250***
(0.000849)

-0.194***
(0.000734)

Variance (millions)

-6.48e-05
(6.42e-05)

1.51e-06***
(3.39e-07)

0.000162***
(4.70e-05)

-0.124***
(0.0114)

1.46e-05
(6.02e-05)

Deductible (hundreds)

0.0510***
(0.00279)

-0.341***
(0.00175)

-0.233***
(0.00243)

-0.709***
(0.00351)

-0.713***
(0.00247)

1.162***
(0.0146)

0.326***
(0.0225)

-0.136
(8,047)

1.503***
(0.120)

-1.269***
(0.0422)

0.356***
(0.00893)

-1.065***
(0.00654)

-0.184***
(0.00749)

0.281***
(0.00860)

0.328***
(0.00934)

0.683***
(0.0244)

5.198***
(0.0208)

1.067***
(0.0378)

-4.636***
(0.0432)

-5.149***
(0.0361)

0.175***
(0.00144)

0.275***
(0.00264)

0.181***
(0.00245)

0.150***
(0.00268)

0.334***
(0.00191)

Yes

Yes

Yes

Yes

Yes

464,543

566,962

602,992

614,714

629,225

Full gap coverage
Generic gap coverage
Cost sharing
Number of top 100 drugs on
formulary
Brand dummies
Number of people

A11

Table A7 reports results from estimating the model in column (1) of AGâ€™s Table 3 for each
year from 2006 through 2010. As shown, the premium coefficient is slightly below the OOP coefficient for 2008, 2009 and 2010, and the variance coefficient has a negative sign for both 2009
and 2010.
TABLE A7â€” SENSITIVITY OF AGâ€™S BASE RESULTS TO THE STUDY YEAR
2006

2007

2008

2009

2010

Premium (hundreds)

-0.352***
(0.00110)

-0.441***
(0.00111)

-0.342***
(0.000832)

-0.287***
(0.000793)

-0.236***
(0.000719)

OOP costs (hundreds)

-0.161***
(0.000477)

-0.176***
(0.000516)

-0.382***
(0.000710)

-0.297***
(0.000680)

-0.296***
(0.000599)

Variance (millions)

-0.000136***
(5.28e-05)

4.76e-07*
(2.74e-07)

0.000252***
(3.79e-05)

-1.269***
(0.0128)

-0.000307***
(5.09e-05)

CMS quality index

4.208***
(0.00994)

5.064***
(0.00925)

1.040***
(0.00425)

1.332***
(0.00318)

-0.0115***
(0.00260)

no

no

no

no

no

464,543

566,962

602,992

614,714

629,225

Brand dummies
Number of people

Table A8 reports the correlation coefficients between placebo plan characteristics and real
plan characteristics calculated across all consumer-plan observations.
TABLE A8â€” CORRELATIONS BETWEEN PLACEBO AND REAL PLAN CHARACTERISTICS

premium
OOP costs
variance
deductible
full gap coverage
generic gap coverage
cost sharing
top 100 count
count 8
count 9
count D
count d
count e
count k
count l
count o
count r
count x

premium

OOP costs

variance

deductible

1.00
-0.10
0.00
-0.30
0.33
0.30
-0.33
0.21
-0.01
0.06
0.06
-0.01
0.01
0.07
-0.06
0.03
0.06
-0.15

1.00
0.01
0.13
-0.05
-0.08
0.18
-0.10
-0.02
-0.03
0.00
0.00
0.03
-0.02
0.01
0.00
-0.01
0.04

1.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

1.00
-0.13
-0.30
-0.04
-0.09
-0.08
-0.07
-0.03
0.04
0.08
-0.07
0.04
0.01
-0.03
0.10

full gap generic gap
coverage coverage

1.00
-0.06
0.04
0.08
-0.03
0.08
0.09
-0.05
-0.06
-0.11
-0.01
-0.03
0.05
0.07

1.00
-0.08
0.09
-0.02
0.06
-0.01
0.11
0.07
0.14
-0.03
0.11
-0.01
-0.29

cost
sharing

top 100
count

1.00
-0.43
-0.06
-0.03
0.01
-0.05
0.02
-0.13
0.06
0.01
0.02
0.15

1.00
0.05
0.07
-0.05
0.06
0.02
0.07
-0.03
0.04
-0.03
-0.14

A12

TABLE A9â€” RESULTS FROM MODELS WITH PLACEBO PLAN CHARACTERISTICS
Variable

Coefficient

Count of 8's

-0.0243***
(0.00568)

Count of 9's

-0.0523***
(0.00604)

Count of D's

-0.0154**
(0.00653)

Count of d's

0.158***
(0.00701)

Count of e's

0.0929***
(0.00737)

Count of k's

-0.215***
(0.00450)

Count of l's

0.0301***
(0.00631)

Count of o's

-0.0522***
(0.00782)

Count of r's

-0.228***
(0.00716)

Premium (hundreds)

-0.429***
(0.00260)

OOP costs (hundreds)

-0.108***
(0.000571)

Variance (millions)

-5.11e-05
(6.38e-05)

Deductible (hundreds)

-0.0250***
(0.00315)

Full gap coverage
Generic gap coverage
Cost sharing
Number of top 100 drugs on
formulary
Brand dummies
Number of people

1.314***
(0.0151)
0.383***
(0.00913)
1.019***
(0.0254)
0.172***
(0.00141)
Yes

464,543

A13

Table A10 shows results provided to us by AG regarding the placebo test. It also compares the implied WTP for actual plan financial attributes from AGâ€™s 2011
article, our replication of them, their new results and our replication of them. The
results on the financial attributes show that their new results diverge from their
old ones by at least $90 for 4 of the 5 attributes. In contrast, all of ours are within
$65. The lower half of the Table reports the results from their placebo attributes
and our replication of their placebo model. For several reasons these results are
not directly comparable to the results we report, yet they yield similar qualitative
insights: first, they replaced our count variables for each alphanumeric with indicator variables for any positive count of the alphanumeric. Although this makes it
impossible to isolate the marginal effects comparable to the financial attributes, to
facilitate comparison we replicate their approach here. Second, they stated that
they normalized these placebo attributes to zero, relative to whether a â€œ9â€ is present, but they did not implement any similar normalization for the financial attributes. Third, two separate values are reported for the presence of â€œkâ€, and no values are reported for the presence of an â€œeâ€. Nonetheless, as with our results the
test implies that these imaginary attributes influence peopleâ€™s PDP choices in
economically meaningful ways. For example, AGâ€™s results imply that people
would be willing to pay $117 more for a plan with a â€œdâ€, â€œoâ€ and â€œlâ€ in the encrypted plan ID than for a plan with three â€œ9sâ€, whereas they would pay $124 for
a plan with three â€œ9sâ€ to avoid a plan with an â€œ8â€, â€œDâ€ and â€œxâ€. Both of these, as
well as a number of other combinations, exceed the magnitude estimated for of all
of the real plan attributes in AG 2011 other than full gap coverage.

A14

TABLE A10â€” COMPARING ESTIMATED WILLINGNESS TO PAY FOR REAL AND PLACEBO PLAN CHARACTERISTICS FROM AG 2011 BASELINE
MODEL OUR REPLICATION OF AG, AND NEW RESULTS PROVIDED BY AG

AG 2011

Decreasing the deductible from $250 to $0
Covering one additional "top 100" drug
Adding generic gap coverage
Increasing cost sharing from 25% to 65%
Adding full gap coverage
Encrypted plan ID includes at least one
â€œdâ€
â€œoâ€
â€œkâ€--result 1
â€œkâ€--result 2
â€œlâ€
â€œrâ€
"9"
"e"
â€œ8â€
â€œDâ€
â€œxâ€

WTP ($)
80
50
50
80
300

Our replication
Difference
from AG
WTP ($) 2011 ($)
15
-65
40
-10
89
39
95
15
306
6

AG placebo
specification
Difference
from AG
WTP ($)
2011
293
213
9
-41
142
92
541
461
434
134

60
40
29
-27
17
16
Reference
Not provided
-7
-34
-83

Our replication
Difference
from AG
WTP ($)
2011
20
-60
39
-11
87
37
92
12
297
-3
-97
-32
11
--40
14
-30
-60
-37
-38
-77

A15

TABLE A11â€” RESULTS FROM FIVE LARGEST REGIONS DEFINING BRAND DUMMIES BASED ON
CONTRACT ID

region region region region region
25
17
11
22
4
Estimated parameter ratios
premium / OOP

1.3
(0.0)

7.3
(0.2)

9.7
(0.3)

5.7
(0.2)

78.9
(5.4)

variance / premium

0.0
(0.0)

0.0
(0.0)

0.0
(0.0)

-0.3
(0.1)

0.0
(0.0)

deductible / premium

-3.0
(0.1)

0.5
(0.0)

0.3
(0.0)

-0.2
(0.0)

0.0
(0.0)

full gap / premium

-2.9
(0.1)

-3.3
(0.1)

-4.3
(0.0)

-3.2
(0.1)

-4.4
(0.0)

generic gap / premium

0.6
(0.5)

1.8
(0.1)

-0.9
(0.0)

-2.3
(0.1)

-1.8
(0.0)

cost share / premium

-2.9
(0.8)

2.4
(0.1)

-2.8
(0.2)

5.0
(0.2)

1.8
(0.1)

top 100 / premium

-0.3
(0.0)

-0.3
(0.0)

-0.2
(0.0)

-0.3
(0.0)

-0.1
(0.0)

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

101

19

25

25

19

19

9

17

8

20

41

42

43

47

44

17

17

19

21

19

7

6

8

6

6

25

25

27

25

78

76

76

78

8.2

7.8

8.6

9.4

79

76

72

82

27
469

26
543

25
517

16
606

37,939

30,138

29,387

24,162

PDP Menu
# plans
# brands
# plans w/ gap coverage

23
# plans w/ no deductible
Consumers
mean age
76
% with dementia
6.2
% off cost-var frontier
74
% off cost-var-brand frontier
36
621
mean potential savings
46,997
number

A16

Table A12 replicates the results in Table 5 after limiting the sample to white
females under 80 who have not been diagnosed with Alzheimerâ€™s, dementia, or
depression. See the discussion of Table 5 for additional details.
TABLE A12: RESULTS FROM MODELS IN TABLE 5 BUT WITH THE SAMPLE RESTRICTED TO WHITE
FEMALES AGE<80 WITHOUT ALZHEIMERâ€™S DISEASE OR DEMENTIA OR DEPRESSION

United region region region region region
States
25
17
11
22
4
Decision utility parameters
premium / OOP

3.3
(0.0)

1.0
(0.1)

5.6
(0.2)

4.2
(0.3)

1.7
(0.2)

-5.0
(2.1)

variance / premium

0.0
(0.0)

0.0
(0.0)

0.0
(0.0)

-0.1
(0.0)

-0.2
(0.2)

-0.8
(0.6)

deductible / premium

-0.1
(0.0)

-3.6
(0.3)

0.1
(0.0)

0.3
(0.1)

-0.7
(0.2)

4.9
(1.8)

full gap / premium

-2.5
(0.0)

-2.6
(0.2)

-3.0
(0.1)

-3.3
(0.2)

1.6
(0.9)

-8.3
(1.6)

generic gap / premium

-0.8
(0.0)

2.0
(1.0)

1.9
(0.2)

-0.1
(0.1)

-3.6
(0.6)

3.2
(2.0)

cost share / premium

-2.8
(0.1)

-4.2
(1.7)

2.7
(0.3)

-9.1
(0.6)

5.7
(1.2)

-30.5
(11.9)

top 100 / premium

-0.4
(0.0)

-0.3
(0.0)

-0.3
(0.0)

-0.4
(0.0)

-0.6
(0.1)

-0.1
(0.1)

31
11
9,869

63
4
9,174

--6,916

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted
Number of consumers

41
94
18
7
27
8
155,115 17,196 11,448

A17

Table A13 reports summary statistics of the distribution of region-level results,
restricted to the 24 regions with statistically significant positive estimates for the
marginal utility of income. The last row reports the premium-to-OOP ratio that is
predicted from an extended version of AGâ€™s DU model from equation (4) that allows the premium-to-OOP ratio to vary with the number of plans in the choice
set, the number of brands, the number of plans with gap coverage, the number of
plans with zero deductible, the consumerâ€™s age, and an indicator for whether the
consumer is diagnosed with dementia including Alzheimerâ€™s disease. Coefficient
estimates are reported in Table A16.
TABLE A13â€”SUMMARY STATISTICS OF THE DISTRIBUTION OF REGION-SPECIFIC ESTIMATED PARAMETER RATIOS, PDP MENU ATTRIBUTES, CONSUMER ATTRIBUTES AND NONPARAMETRIC OUTCOMES, 2006
Mean

Standard
25th
75th
deviation Minimum Percentile Median Percentile Maximum

Estimated parameter ratios
premium / OOP
variance / premium
deductible / premium
full gap / premium
generic gap / premium
cost share / premium
top 100 / premium

4.8
-0.2
-0.4
-3.0
-1.6
-4.5
-0.4

2.8
0.3
1.8
1.7
2.7
13.0
0.2

1.1
-0.8
-7.5
-4.4
-9.5
-25.8
-0.9

2.7
-0.4
-0.1
-4.2
-1.7
-10.7
-0.6

4.2
-0.2
0.1
-3.3
-1.1
-6.0
-0.4

6.6
0.0
0.2
-2.5
-0.4
-2.0
-0.3

12.3
0.6
1.1
0.6
1.6
48.1
-0.2

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

42.1
14.9

24.1
13.1

17.7
3.3

25.1
8.8

33.6
11.3

54.5
15.9

109.9
68.4

42
19
7

9
4
1

38
17
6

41
18
6

42
19
7

44
20
7

47
23
9

16,638
76
7
75
19
506

11,036
15
2
15
6
103

3,710
75
6
67
8
355

7,035
75
7
72
16
485

14,712
76
8
75
19
508

23,659
76
8
78
23
535

46,997
78
9
82
34
621

4.1

0.6

3.3

3.8

4.0

4.2

5.9

PDP Menu
# plans
# brands
# plans w/ gap coverage
Consumers
number
mean age
% with Alzheimer's
% off cost-var frontier
% off cost-var-brand frontier
mean potential savings
premium / oop ratio predicted
by interaction model

A18

TABLE A14â€”REGION-SPECIFIC ESTIMATED PARAMETER RATIOS, PDP MENU ATTRIBUTES, CONSUMER ATTRIBUTES AND NONPARAMETRIC OUTCOMES, 2006
region region region region region region region region
1
2
3
4
5
6
7
8
Estimated parameter ratios
premium / OOP

3.2
(0.3)

12.3
(0.5)

-0.7
(0.4)

3.1
(1.1)

3.9
(0.6)

0.3
(0.3)

0.3
(0.3)

6.7
(0.3)

variance / premium

-0.2
(0.1)

-0.2
(0.1)

5.7
(3.8)

0.6
(0.5)

-0.4
(0.2)

-0.3
(0.5)

-6.4
(7.2)

0.0
(0.0)

deductible / premium

0.3
(0.0)

1.7
(0.7)

-7.5
(2.9)

0.3
(0.1)

-10.9
(11.5)

6.3
(6.3)

0.2
(0.0)

full gap / premium

-4.3
(0.1)

-18.4
(8.9)

0.5
(1.9)

-3.0
(0.3)

23.1
(28.4)

29.8
(37.4)

-4.3
(0.1)

generic gap / premium

-2.9
(0.1)

-1.6
(0.0)

1.1
(2.3)

-8.8
(2.9)

0.2
(0.4)

-10.6
(9.1)

15.0
(18.0)

-1.5
(0.1)

cost share / premium

-25.8
(1.7)

-5.6
(0.2)

22.2
(16.8)

48.1
(18.0)

-9.7
(1.8)

-9.5
(9.4)

-107.7
(112.9)

-3.9
(0.2)

top 100 / premium

-0.5
(0.0)

-0.2
(0.0)

0.3
(0.4)

-0.5
(0.2)

-0.6
(0.1)

-1.5
(1.4)

-4.1
(4.1)

-0.3
(0.0)

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

29

31

-193

110

34

421

403

24

11

22

-12

68

7

23

42

13

41

44

46

44

47

52

41

38

19

22

22

20

22

23

19

17

6

7

6

6

6

8

6

7

24

28

25

25

26

30

23

22

18,248

10,661

24,162

10,570

19,417

11,148

19,447

PDP Menu
# plans
# brands
# plans w/ gap coverage
# plans w/ zero deductible

Consumers
5,729
number
mean age
76
% with Alzheimer's
7.0
% off cost-var frontier
67
% off cost-var-brand frontier
10
355
mean potential savings
premium / oop ratio predicted
by interaction model

3.9

77

76

78

76

76

75

75

7.7

7.6

9.4

7.8

8.0

7.1

6.6

76

71

82

77

74

73

68

19
491

9
463

8
606

14
493

19
475

17
511

16
533

5.7

3.3

3.6

3.3

3.5

3.7

4.2

Note: the last row reports the premium-to-oop ratio predicted from a generalized version of AGâ€™s model that allows the ratio to vary with the proxy measures for menu complexity and cognitive ability. For more details see the explanation of Tables A13 and A16.

A19

TABLE A14 (CONTINUED)â€”REGION-SPECIFIC ESTIMATED PARAMETER RATIOS, PDP MENU ATTRIBUTES, CONSUMER ATTRIBUTES AND NONPARAMETRIC OUTCOMES, 2006

region region region region region region region region
9
10
11
12
13
14
15
16
Estimated parameter ratios
premium / OOP

0.3
(0.3)

7.8
(0.4)

3.3
(0.2)

6.2
(0.3)

5.5
(0.4)

2.1
(0.2)

3.6
(0.2)

2.6
(0.2)

variance / premium

-11.1
(12.0)

-0.2
(0.1)

0.0
(0.0)

-0.4
(0.1)

-0.2
(0.1)

-0.4
(0.2)

-0.7
(0.1)

0.0
(0.2)

deductible / premium

-17.3
(18.9)

-0.1
(0.0)

0.1
(0.0)

-0.1
(0.0)

0.6
(0.0)

0.2
(0.1)

-0.1
(0.0)

0.0
(0.1)

full gap / premium

13.5
(20.1)

-4.4
(0.1)

-3.3
(0.1)

-4.4
(0.1)

-4.2
(0.1)

-1.2
(0.5)

-4.2
(0.1)

-2.5
(0.3)

generic gap / premium

21.8
(25.5)

-1.1
(0.1)

-0.1
(0.1)

-1.4
(0.1)

-1.0
(0.2)

0.5
(0.3)

-1.2
(0.1)

-0.6
(0.1)

cost share / premium

40.0
(44.9)

-2.0
(0.2)

-10.9
(0.6)

-3.5
(0.2)

-12.7
(0.6)

-14.7
(1.5)

-11.0
(0.6)

-7.6
(0.6)

top 100 / premium

-1.4
(1.3)

-0.2
(0.0)

-0.5
(0.0)

-0.4
(0.0)

-0.4
(0.0)

-0.9
(0.1)

-0.5
(0.0)

-0.4
(0.0)

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

398

24

38

27

34

66

40

42

61

12

9

16

21

9

11

7

45

42

43

41

40

43

42

45

21

19

20

19

19

20

19

19

6

7

8

6

6

7

7

9

24

24

25

23

23

25

25

29

17,268

30,138

16,928

10,389

15,932

23,832

9,340

PDP Menu
# plans
# brands
# plans w/ gap coverage
# plans w/ zero deductible

Consumers
7,650
number
mean age
76
% with Alzheimer's
7.4
% off cost-var frontier
79
% off cost-var-brand frontier
20
558
mean potential savings
premium / oop ratio predicted
by interaction model

3.3

75

76

75

76

76

76

75

8.0

7.8

7.9

7.5

7.7

7.0

6.1

79

76

71

74

72

76

78

20
495

15
543

23
522

22
499

16
495

24
540

21
427

3.9

4.0

3.7

3.9

3.9

4.0

4.6

Note: the last row reports the premium-to-oop ratio predicted from a generalized version of AGâ€™s model that allows the ratio to vary with the proxy measures for menu complexity and cognitive ability. For more details see the explanation of Tables A13 and A16.

A20

TABLE A14 (CONTINUED)â€”REGION-SPECIFIC ESTIMATED PARAMETER RATIOS, PDP MENU ATTRIBUTES, CONSUMER ATTRIBUTES AND NONPARAMETRIC OUTCOMES, 2006

region region region region region region region region
17
18
19
20
21
22
23
24
Estimated parameter ratios
premium / OOP

7.0
(0.2)

4.4
(0.3)

-0.2
(0.3)

4.7
(0.4)

2.2
(0.6)

1.9
(0.1)

8.1
(0.6)

9.9
(0.6)

variance / premium

0.0
(0.0)

-0.6
(0.1)

0.0
(0.0)

-0.3
(0.1)

0.0
(0.3)

-0.8
(0.2)

-0.2
(0.1)

-0.4
(0.1)

deductible / premium

0.0
(0.0)

0.2
(0.0)

15.0
(25.6)

0.0
(0.1)

-1.6
(0.7)

-0.5
(0.1)

0.2
(0.0)

0.1
(0.0)

full gap / premium

-3.5
(0.1)

-3.4
(0.1)

-46.6
(74.3)

-3.5
(0.2)

-3.3
(0.7)

0.6
(0.5)

-3.7
(0.1)

-4.0
(0.1)

generic gap / premium

1.6
(0.1)

-1.1
(0.1)

-1.8
(0.2)

-9.5
(2.9)

-2.8
(0.3)

-0.3
(0.1)

-0.8
(0.1)

cost share / premium

3.8
(0.2)

-6.8
(0.4)

32.5
(58.0)

-1.3
(0.5)

3.2
(2.4)

5.0
(0.6)

-2.5
(0.3)

-2.2
(0.2)

top 100 / premium

-0.4
(0.0)

-0.4
(0.0)

3.5
(6.4)

-0.3
(0.0)

-0.6
(0.1)

-0.7
(0.0)

-0.4
(0.0)

-0.2
(0.0)

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

18

31

-295

24

40

62

20

23

9

11

-50

10

8

3

10

16

42

41

40

38

39

47

42

40

18

18

17

17

18

22

18

17

6

6

6

6

6

6

7

7

25

25

24

23

24

27

25

25

13,492

7,317

6,785

4,265

29,387

6,880

7,499

PDP Menu
# plans
# brands
# plans w/ gap coverage
# plans w/ zero deductible

Consumers
37,939
number
mean age
78
% with Alzheimer's
8.2
% off cost-var frontier
79
% off cost-var-brand frontier
15
469
mean potential savings
premium / oop ratio predicted
by interaction model

4.0

76

75

75

75

76

76

77

7.9

8.5

6.9

7.8

8.6

7.6

7.5

73

79

74

75

72

79

78

21
491

30
591

26
520

19
547

18
517

24
520

24
536

4.1

4.1

4.3

4.2

3.5

4.1

4.5

Note: the last row reports the premium-to-oop ratio predicted from a generalized version of AGâ€™s model that allows the ratio to vary with the proxy measures for menu complexity and cognitive ability. For more details see the explanation of Tables A13 and A16.

A21

TABLE A14 (CONTINUED)â€”REGION-SPECIFIC ESTIMATED PARAMETER RATIOS, PDP MENU ATTRIBUTES, CONSUMER ATTRIBUTES AND NONPARAMETRIC OUTCOMES, 2006

region region region region region region region region
25
26
27
28
29
30
31
32
Estimated parameter ratios
premium / OOP

1.1
(0.0)

-0.2
(0.9)

4.5
(0.6)

1.5
(0.7)

1.8
(2.0)

3.9
(0.4)

-2.2
(0.7)

5.6
(0.4)

variance / premium

0.0
(0.0)

0.9
(7.1)

-0.8
(0.2)

0.1
(0.3)

-3.1
(3.6)

0.0
(0.0)

2.7
(1.0)

0.0
(0.0)

deductible / premium

-3.6
(0.2)

6.5
(22.6)

0.2
(0.1)

-0.7
(0.6)

0.8
(0.5)

1.1
(0.1)

1.5
(0.4)

0.5
(0.0)

full gap / premium

-2.9
(0.1)

-45.5
(147.7)

-3.1
(0.3)

-0.3
(2.3)

1.8
(7.3)

-2.3
(0.3)

-9.1
(1.5)

-3.1
(0.1)

generic gap / premium

0.8
(0.6)

-0.7
(0.2)

-2.9
(1.3)

0.3
(1.4)

-0.8
(0.3)

cost share / premium

-3.2
(0.9)

-29.3
(114.5)

-6.4
(0.8)

-10.1
(5.0)

-25.8
(25.8)

-22.1
(1.9)

0.3
(2.1)

-6.4
(0.4)

top 100 / premium

-0.4
(0.0)

62.6
(225.2)

-0.3
(0.0)

-0.7
(0.3)

-0.7
(0.7)

-0.6
(0.0)

0.3
(0.2)

-0.4
(0.0)

Welfare loss (% of costs)
Îµâ‰¡0
Îµ is unrestricted

92

-324

33

79

109

59

-86

31

24

-118

10

4

9

32

-29

15

41

43

43

43

44

45

44

47

23

19

19

20

20

22

20

20

7

6

7

6

7

6

6

7

23

26

26

25

25

25

23

28

1,587

3,710

4,926

1,703

12,314

5,594

23,141

PDP Menu
# plans
# brands
# plans w/ gap coverage
# plans w/ zero deductible

Consumers
46,997
number
mean age
76
% with Alzheimer's
6.2
% off cost-var frontier
74
% off cost-var-brand frontier
34
621
mean potential savings
premium / oop ratio predicted
by interaction model

5.9

-1.1
(0.1)

75

76

75

75

76

76

76

6.9

7.4

5.7

6.4

6.6

6.3

6.6

74

73

69

78

74

76

78

13
414

18
468

13
444

17
510

18
483

20
532

17
521

3.9

4.1

3.7

3.7

3.4

3.4

3.8

Note: the last row reports the premium-to-oop ratio predicted from a generalized version of AGâ€™s model that allows the ratio to vary with the proxy measures for menu complexity and cognitive ability. For more details see the explanation of Tables A13 and A16.

A22

FIGURE A3â€”RATIO OF PREMIUM-TO-OOP COEFFICIENTS IN 2006, BY CMS REGION USING AGâ€™S
DEFINITION OF BRAND DUMMIES BASED ON CONTRACT ID
Note: The figure reports the premium-to-OOP coefficient ratio obtained by estimating region-specific models with contract
id dummies. The econometric specification is the same as the national model in column 2 of Table 4. In regions with lightshaded numbers, we fail to reject the null hypothesis that the marginal utility of income is negative at the 5% level. All estimates are statistically indistinguishable from 1 at the 5% level.

A23

Table A15 provides the coefficients and standard errors from meta-regressions
of the conditional relationship between the premium-to-OOP ratio and proxy
measures for menu complexity and cognitive ability. The models are limited to
the 24 regions with statistically significant positive estimates for the marginal utility of income. The main text provides additional details.
TABLE A15: RESULTS FROM MODELS OF THE REGION-LEVEL ESTIMATES FOR AGâ€™S PARAMETRIC
MEASURES OF CHOICE QUALITY ON PROXY MEASURES FOR MENU COMPLEXITY AND COGNITIVE
ABILITY
(1)

(2)

(3)

(4)

(5)

% welfare loss
premium-to-OOP coef ratio

Îµâ‰¡0

Îµâ‰ 0

Number of plans

-0.508
(0.553)

-0.559
(0.577)

1.100
(4.420)

0.707
(2.386)

Number of brands

-0.234
(0.521)

-0.214
(0.553)

7.613*
(4.241)

1.082
(2.289)

Number of plans w/ gap coverage

-0.284
(0.896)

0.0865
(0.943)

0.837
(7.227)

0.703
(3.901)

Number of plans w/ zero deductible

0.858
(0.710)

0.802
(0.725)

-4.213
(5.555)

-2.574
(2.998)

mean age

0.706
(0.960)

0.811
(1.004)

8.567
(7.697)

10.43**
(4.154)

% with Alzheimer's

0.277
(0.861)

0.445
(0.947)

-3.410
(7.261)

0.129
(3.919)

-50.83
(69.39)

-52.80
(71.95)

-678.1
(551.5)

-769.2**
(297.7)

Constant
Observations
R2
Adjusted R2
P-value of model Wald Chi-Square

11.33
(10.30)
24

24

24

24

24

0.151

0.061

0.239

0.404

0.422

-0.028

-0.028

-0.029

0.193

0.218

0.514

0.515

0.523

0.136

0.111

Note: *** p<0.01, ** p<0.05, * p<0.1

A24

To check robustness of the results from the meta-regression in equation (9) we
estimate AGâ€™s DU model (4) after adding interactions between the OOP ratio and
the proxy measures for menu complexity and cognitive ability. This logit model
accounts for variation in menu complexity across CMS regions and for variation
in cognitive ability within and across CMS regions. Each of the interaction coefficients is statistically significant at the 1% level. To evaluate their economic magnitudes we use the estimates to predict how the premium-to-oop ratio would
change as we move from the lowest value of each variable observed in our data to
the highest value, while evaluating all other variables at their means. The resulting
ranges are reported in the last two columns of Table A16. For example, the results
in the first row of the table imply that increasing the number of plans in a consumerâ€™s choice set from 38 plans to 52 plans would decrease the premium-to-oop
ratio from 4.6 to 2.9, contrary to the hypothesis of choice overload.
TABLE A16: ESTIMATED EFFECTS OF PROXY MEASURES FOR MENU COMPLEXITY AND COGNITIVE
ABILITY ON THE PREMIUM-TO-OOP RATIO

Number of plans in choice set
Number of brands in choice set
Number of plans with gap coverage
Number of plans with zero deductible
Age
Dementia including Alzeheimer's

Summary statistics

Econometric estimates

Premium-to-OOP ratio

mean

min

max

interaction standard
with OOP
error

predicted predicted
at the Min at the Max

43.15
20.05
6.67
25.08
76.04
0.08

38
17
6
22
66
0

52
23
9
30
108
1

-0.0035
-0.0014
0.0033
0.0043
0.0002
-0.0102

(0.0004)
(0.0003)
(0.0007)
(0.0005)
(0.0001)
(0.0014)

4.6
4.0
3.7
3.4
3.7
3.8

2.9
3.7
4.1
4.7
4.0
3.5

Note: The estimated coefficients on premium and OOP are -0.406 and -0.066 respectively. Both have p-values of zero out
to four decimal places.

Table A17 provides results from validation tests for the cases where the set of
brands in an estimation region spans the set of brands in the prediction region.
Two pairs of regions meet this criterion in 2006. As a result, we estimate the
AGâ€™s two competing models for region 14 and then use the resulting coefficients

A25

to predict outcomes in region 15, and we use estimates for region 30 to predict
outcomes in region 28. Both region pairs are similar in their consumer populations and PDP menu complexity. AGâ€™s EUM model yields closer out-of-sample
predictions than their DU model in every case but one. The shading indicates
which prediction is closer to the data.
TABLE A17: RESULTS FROM BETWEEN-REGION VALIDATION TESTS FOR THE ONLY TWO PAIRS OF
REGIONS IN 2006 FOR WHICH ONE REGIONâ€™S BRANDS ARE NESTED WITHIN THE OTHERâ€™S
region 14 â†’ 15
region 30 â†’ 28
data AG's DU AG's EUM
data AG's DU AG's EUM
In-sample data and predictions
region 14
region 30
Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

11
16
47

11
18
40

13
17
41

6
18
41

6
19
35

9
17
40

1,261
0

1,262
65

1,267
58

1,074
0

1,093
63

1,095
58

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

25
44

25
25
25
25
25
44
44
39
39
39
Out-of-sample data and predictions
region 15
region 28

Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

9
12
50

6
25
32

10
19
40

18
24
42

11
18
40

13
17
41

1,096
0

1,205
102

1,178
70

1,418
0

1,352
67

1,355
57

44
62

30
42

31
46

21
31

27
45

26
44

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

0
0

A26

Table A18 provides results from the national validation test shown in Table 6
except using the root mean square error in predictions across regions in place of
the mean absolute error.

TABLE A18â€” NONRANDOM HOLDOUT SAMPLE TESTS OF MODEL VALIDATION, 2006

In-sample fit

Out-of-sample fit

AG's DU AG's EUM

AG's DU AG's EUM

RMSE

RMSE

data

Using CMS Star Ratings for Quality
Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

13
20
52

0
5
8

7
6
9

9
8
11

7
7
9

1,255
0

16
72

46
55

113
70

88
51

25
37

11
12

15
18

11
14

15
18

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

Using Brand Indicators for Quality
Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

13
20
52

0
2
6

4
4
9

9
9
14

8
9
13

1,256
0

16
82

21
71

102
88

101
70

25
37

0
0

0
0

14
18

13
17

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

Note: RMSE refers to the root mean square error between the regional-level model predictions and data, weighted across
regions by the number of people in the sample in the region. The results are based on every possible pairwise combination
of regions in 2006 except that they exclude regions 33 and 34 (HI and AK), and the lower half also excludes region 26
(NM). Thus the values in the top half are based on the results from all 992 of the possible regional out-of-sample predictions while those in the lower half are based on 930 of them.

A27

Table A19 provides results from the national validation test suggested to us by
Abaluck and Gruber. Specifically, we estimate the models using the 2006 data
from 31 regions and use it to predict a single out-of-sample region, repeated using
each of the 32 regions as the holdout region (excluding Alaska and Hawaii). This
is very similar to an in-sample validation test as the set of plans and plan attributes in the single out-of-sample region is typically very close to being nested
within the in-sample set (see Keane and Wolpin 2007). As before the measures of
market concentration are defined at the region level as that is the policy-relevant
market definition. Hence while the models with brand indicators match the market
concentration perfectly across the 31 in-sample regions in each of the 32 separate
tests (yielding a mean absolute deviation of 0), they do not perfectly predict the
region-level market concentration for any single given in-region sample.

A28

TABLE A19â€” RESULTS FROM THE NATIONAL MODEL VALIDATION TESTS SUGGESTED BY
ABALUCK AND GRUBER

data

In-sample fit

Out-of-sample fit

AG's DU AG's EUM

AG's DU AG's EUM

|model error |

|model error |

Using CMS Star Ratings for Quality
Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

13
20
52

0
2
3

2
2
4

6
6
6

6
6
5

1,255
0

4
63

15
51

61
63

60
51

25
37

11
9

14
17

11
11

14
17

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

Using Brand Indicators for Quality
Percent of consumers choosing:
gap coverage
dominated plan
min cost plan within brand

13
20
52

0
1
7

2
1
8

6
5
8

6
5
9

1,255
0

10
64

14
61

61
71

57
63

25
37

4
6

4
6

5
8

4
7

Median consumer expenditures ($)
premium + OOP
overspending on dominated plans
Market concentration
Hirfindahl-Hirschman index
market share of top brand

Note: | Model error | refers to the mean absolute deviation between the model predictions and data.

A29

